Form 8-K

8-K — Structure Therapeutics Inc.

Accession: 0001104659-26-057226

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001888886

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Results of Operations and Financial Condition

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2613721d1_8k.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (tm2613721d1_ex1-1.htm)

EX-5.1 — EXHIBIT 5.1 (tm2613721d1_ex5-1.htm)

EX-99.1 — EXHIBIT 99.1 (tm2613721d1_ex99-1.htm)

GRAPHIC (tm2613721d1_8kimg01.jpg)

GRAPHIC (tm2613721d1_8kimg02.jpg)

GRAPHIC (tm2613721d1_ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613721d1_8k.htm · Sequence: 1

false

0001888886

True

0001888886

2026-05-07

0001888886

gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

2026-05-07

0001888886

gpcr:OrdinarySharesParValue0.0001PerShareMember

2026-05-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 7, 2026

Structure

Therapeutics Inc.

(Exact name of registrant as specified in its

charter)

Cayman

Islands

001-41608

98-1480821

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

601

Gateway Blvd., Suite

900

South

San Francisco, California

94080

(Address

of principal executive offices)

(Zip

Code)

(Registrant’s

telephone number, including area code): (650)

457-1978

Not Applicable

(Former name or former address, if changed

since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General

Instruction A.2. below):

Written communications pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered

pursuant to Section 12(b) of the Act:

Title

of Each Class

Name Of Each Exchange

Trading Symbol(s)

On Which

Registered

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

GPCR

Nasdaq

Global Market

Ordinary

shares, par value $0.0001 per share*

True

Nasdaq

Global Market*

* Not for trading, but only in connection with the registration of

the American Depositary Shares

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01

Entry into a Material Definitive Agreement.

On May 7, 2026, Structure Therapeutics Inc. (the “Company”)

amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated,

the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales

Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing

three ordinary shares, $0.0001 par value per ordinary share. The Amended and Restated Sales Agreement modifies the Sales Agreement to

remove the aggregate offering amount of ADSs the Company may offer and sell thereunder (the “ATM Shares”).

The foregoing description of the Amended and Restated Sales Agreement

does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended and Restated Sales Agreement,

which is attached as Exhibit 1.1 hereto and is incorporated by reference herein.

Item 2.02

Results of Operations and Financial Condition.

On May 7, 2026, the Company issued a press release providing a corporate

update and announcing its financial results for the first quarter ended March 31, 2026. The full text of the press release is furnished

as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K (including Exhibit

99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the

“Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference

into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth

by specific reference in such filing.

Item 8.01

Other Events.

On May 7, 2026, in connection with Amended and Restated Sales Agreement,

the Company filed a prospectus supplement (the “Prospectus Supplement”) to the prospectus filed on August 6, 2025 (the “Prospectus”)

with the Securities and Exchange Commission as part of the Company’s Registration Statement on Form S-3ASR (File No. 333-289326).

The Company filed the Prospectus Supplement to increase the ATM Shares available to be sold pursuant to the terms of the Amended and Restated

Sales Agreement by an additional $150,000,000, for an aggregate offering price of up to $400,000,000.

The Prospectus Supplement should be read in conjunction with the Prospectus,

and is qualified by reference thereto, except to the extent that the information therein amends or supersedes the information contained

in the Prospectus. The Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus

and any future amendments or supplements thereto.

As of the date of the Prospectus Supplement, the Company previously

sold an aggregate of 3,040,000 ATM Shares for gross proceeds of approximately $58,520,000 under the Sales Agreement.

A copy of the opinion of Travers Thorp Alberga relating to the validity

of the ATM Shares is attached as Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

1.1

Amended and Restated Sales Agreement, by and among Structure Therapeutics Inc., Leerink Partners LLC and Cantor Fitzgerald & Co., dated May 7, 2026.

5.1

Opinion of Travers Thorp Alberga.

23.1

Consent of Travers Thorp Alberga (included in Exhibit 5.1).

99.1

Press Release dated May 7, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Structure Therapeutics Inc.

Date: May 7, 2026

By:

/s/ Raymond Stevens

Raymond Stevens, Ph.D.

Chief Executive Officer

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: tm2613721d1_ex1-1.htm · Sequence: 2

Exhibit 1.1

STRUCTURE THERAPEUTICS INC.

American Depositary Shares

Each Representing 3 Ordinary Shares

($0.0001 Par Value Per Ordinary Share)

AMENDED AND RESTATED SALES AGREEMENT

May 7,

2026

LEERINK PARTNERS LLC

CANTOR FITZGERALD & CO.

c/o Leerink Partners LLC

1301 Avenue of the Americas, 5th Floor

New York, New York 10019

c/o Cantor Fitzgerald & Co.

110 East 59th Street, 6th Floor

New York, NY 10022

Ladies and Gentlemen:

Reference is made to that certain Sales Agreement, entered into as

of August 6, 2025 (the “Original Sales Agreement”), by and among Structure Therapeutics Inc., an exempted

company with limited liability incorporated under the laws of the Cayman Islands (the “Company”), Leerink Partners

LLC and Cantor Fitzgerald & Co. (each, an “Agent” and together, the “Agents”).

The Company and the Agents now intend to enter into this Amended and Restated Sales Agreement (this “Agreement”)

to amend and restate the terms of the Original Sales Agreement in its entirety. Therefore, the Company confirms its agreement with the

Agents as follows:

1.            Issuance

and Sale of ADSs. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions

set forth herein, it may issue and sell through the Agents American Depositary Shares (the “ADSs”), each representing

3 ordinary shares, $0.0001 par value per ordinary share, of the Company (the “Ordinary Shares”), subject to

the limitations set forth in Section 5(c) (the “Placement ADSs”). The ADSs will be evidenced by American

Depositary Receipts (“ADRs”) to be issued pursuant to that certain deposit agreement, dated as of February 2, 2023 (the

“Deposit Agreement”), among the Company, JPMorgan Chase Bank, N.A., as depositary (the “Depositary”),

and holders and beneficial owners from time to time of ADRs evidencing ADSs issued thereunder. Notwithstanding anything to the contrary

contained herein, the parties hereto agree that compliance with the limitation set forth in this Section 1 on the aggregate gross

sales price of Placement ADSs that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the

Company, and that the Agents shall have no obligation in connection with such compliance. The issuance and sale of Placement ADSs through

the Agents will be effected pursuant to the Registration Statement (as defined below) filed by the Company with the Securities and Exchange

Commission (the “Commission”) prior to the date hereof and automatically declared effective by the Commission,

although nothing in this Agreement shall be construed as requiring the Company to issue any Placement ADSs.

The Company has filed, in accordance with the provisions of the Securities

Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Securities Act”),

with the Commission a registration statement on Form S-3, including (a) a base prospectus, relating to certain securities, including

the Placement ADSs, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has

filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations

thereunder (collectively, the “Exchange Act”), and (b) a prospectus, included as part of such registration

statement, specifically relating to the Placement ADSs to be issued from time to time pursuant to this Agreement (as amended or supplemented

from time to time, the “ATM Prospectus”). The Company will furnish to the Agents, for use by the Agents, copies

of the ATM Prospectus and the base prospectus included as part of such registration statement at the time it became effective. Except

where the context otherwise requires, such registration statement, including all amendments thereto and all documents filed as part thereof

or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with

the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant

to Rule 430B or Rule 462(b) under the Securities Act, is herein called the “Registration Statement.”

The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented

by the ATM Prospectus, in the form in which such prospectus and/or ATM Prospectus have most recently been filed by the Company with the

Commission pursuant to Rule 424(b) under the Securities Act, together with any “issuer free writing prospectus”

(as used herein, as defined in Rule 433 under the Securities Act (“Rule 433”)), relating to the Placement

ADSs that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i),

in each case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the

Company’s records pursuant to Rule 433(g), is herein called the “Prospectus.”

Any reference herein to the Registration Statement, the ATM Prospectus,

the Prospectus or any issuer free writing prospectus shall be deemed to refer to and include the documents, if any, that are or are deemed

to be incorporated by reference therein (the “Incorporated Documents”), including, unless the context otherwise

requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms “amend,”

“amendment” or “supplement” with respect to the Registration Statement, the ATM Prospectus, the Prospectus or

any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after

the most-recent effective date of the Registration Statement, or the respective dates of the ATM Prospectus, Prospectus or such issuer

free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to

the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to include the most recent copy filed

with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic

Application system when used by the Commission (collectively, “EDGAR”).

2.            Placements.

Each time that the Company wishes to issue and sell any Placement ADSs through an Agent hereunder (each, a “Placement”),

it will notify the Agent (the “Designated Agent”) by email notice (or other method mutually agreed to in writing

by the parties) (each such notice, a “Placement Notice”) containing the parameters in accordance with which

it desires such Placement ADSs to be sold, which at a minimum shall include the maximum number or amount of Placement ADSs to be sold,

the time period during which sales are requested to be made, any limitation on the number or amount of Placement ADSs that may be sold

in any one Trading Day (as defined in Section 3) and any minimum price below which sales may not be made, a form of which containing

such minimum sales parameters is attached hereto as Schedule 1. The Placement Notice must originate from one of the individuals

authorized to act on behalf of the Company and set forth on Schedule 2 (with a copy to each of the other individuals from

the Company listed on such Schedule 2), and shall be addressed to each of the recipients from the Designated Agent set forth

on Schedule 2, as such Schedule 2 may be updated by the parties from time to time by sending a written notice

containing a revised Schedule 2 to the other parties in the manner provided in Section 12 (including by email correspondence

to each of the individuals of the Company set forth on Schedule 2, if receipt of such correspondence is actually acknowledged

by any of the individuals to whom the notice is sent, other than via auto-reply). The Placement Notice shall be effective upon receipt

by the Designated Agent unless and until (i) in accordance with the notice requirements set forth in Section 4, the Designated

Agent declines in writing to accept the terms contained therein for any reason, in its sole discretion, which declination must occur within

two Trading Days of the date the Designated Agent receives the Placement Notice, (ii) in accordance with the notice requirements

set forth in Section 4, the Designated Agent suspends sales under the Placement Notice for any reason in its sole discretion, (iii) the

entire amount of the Placement ADSs has been sold pursuant to this Agreement, (iv) in accordance with the notice requirements set

forth in Section 4, the Company suspends sales under or terminates the Placement Notice for any reason in its sole discretion, (v) the

Company issues a subsequent Placement Notice and explicitly indicates that its parameters supersede those contained in the earlier dated

Placement Notice or (vi) this Agreement has been terminated pursuant to the provisions of Section 11. The amount of any discount,

commission or other compensation to be paid by the Company to the Designated Agent in connection with the sale of the Placement ADSs effected

through the Designated Agent shall be calculated in accordance with the terms set forth in Schedule 3. It is expressly acknowledged

and agreed that neither the Company nor the Designated Agent will have any obligation whatsoever with respect to a Placement or any Placement

ADSs unless and until the Company delivers a Placement Notice to the Designated Agent and the Designated Agent does not decline such Placement

Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. In the event of a conflict between

the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control with respect to the matters

covered thereby. For the avoidance of doubt, references in this Agreement to (1) the Company issuing and selling Placement ADSs to

the Agents, and similar or analogous expressions, shall be understood to include references to the Company allotting and issuing the new

Ordinary Shares underlying those Placement ADSs to The Hongkong and Shanghai Banking Corporation Limited, as custodian (the “Depositary

Custodian”) for the Depositary, and procuring the issue of Placement ADSs representing such Ordinary Shares by the Depositary

or its nominee to the Agents; and (2) the purchase of, or payment for, any Placement ADSs, and similar or analogous expressions,

shall be understood to refer to the subscription for the Ordinary Shares underlying those Placement ADSs, as well as the deposit of the

Ordinary Shares for Placement ADSs representing such Ordinary Shares, and the payment of the subscription moneys in respect of such Ordinary

Shares.

3.            Sale

of Placement ADSs by the Designated Agent. On the basis of the representations and warranties herein contained and subject to the

terms and conditions herein set forth, including Section 5(c), upon the Designated Agent’s acceptance of the terms of a Placement

Notice as provided in Section 2, and unless the sale of the Placement ADSs described therein has been declined, suspended or otherwise

terminated in accordance with the terms of this Agreement, the Designated Agent, for the period specified in the Placement Notice, will

use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws,

rules and regulations and the rules of the Nasdaq Global Market (“Nasdaq”) to sell such Placement

ADSs up to the number or amount specified in, and otherwise in accordance with the terms of, such Placement Notice. The Designated Agent

will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth

on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is

sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day

on which it has made sales of Placement ADSs hereunder setting forth the number or amount of Placement ADSs sold on such Trading Day,

the volume-weighted average price of the Placement ADSs sold and the Net Proceeds (as defined below) payable to the Company. Unless otherwise

specified by the Company in a Placement Notice, the Designated Agent may sell Placement ADSs by any method permitted by law deemed to

be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made directly on or through

Nasdaq, on or through any other existing trading market for the Placement ADSs or to or through a market maker. If expressly authorized

by the Company (including in a Placement Notice), the Agent may also sell Placement ADSs in negotiated transactions and block trades.

Notwithstanding the provisions of Section 6(nn), except as may be otherwise agreed by the Company and the Designated Agent, the Designated

Agent shall not purchase Placement ADSs on a principal basis pursuant to this Agreement unless the Company and the Designated Agent enter

into a separate written agreement setting forth the terms of such sale. The Company acknowledges and agrees that (i) there can be

no assurance that the Designated Agent will be successful in selling Placement ADSs, (ii) the Designated Agent will incur no liability

or obligation to the Company or any other person or entity if it does not sell Placement ADSs for any reason other than a failure by the

Designated Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state

and federal laws, rules and regulations and the rules of Nasdaq to sell such Placement ADSs as required under this Agreement

and (iii) the Designated Agent shall be under no obligation to purchase Placement ADSs on a principal basis pursuant to this Agreement

unless the Company and the Designated Agent enter into a separate written agreement setting forth the terms of such sale. For the purposes

hereof, “Trading Day” means any day on which the ADSs are purchased and sold on Nasdaq.

4.              Suspension

of Sales.

(a)            The

Company or the Designated Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals

of the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals

to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by email correspondence to each of the individuals

of the other party set forth on Schedule 2), suspend any sale of Placement ADSs; provided, however, that such

suspension shall not affect or impair either party’s obligations with respect to any Placement ADSs sold hereunder prior to the

receipt of such notice. While a suspension pursuant to this Section 4(a) is in effect, any obligation under Sections 7(m), 7(n),

7(o), 7(p), 7(q), 7(r) 7(s) and 7(t), with respect to the delivery of certificates, opinions, or comfort letters to the Agent,

shall be waived; provided, that upon delivery of a Placement Notice following a Representation Date, the Company shall be subject to the

obligations set forth in Sections 7(m), 7(n), 7(o), 7(p), 7(q), 7(r), 7(s) and 7(t) as applicable. Each of the parties agrees

that no such notice under this Section 4 shall be effective against the other party unless notice is sent by one of the individuals

named on Schedule 2 hereto to the other party in writing (including by email correspondence to each of the individuals of

the other party set forth on Schedule 2, if receipt of such correspondence is actually acknowledged by any of the individuals

to whom the notice is sent, other than via auto-reply).

(b)            Notwithstanding

any other provision of this Agreement, during any period in which the Company is, or could be deemed to be, in possession of material

non-public information, the Company and the Agents agree that (i) no sale of Placement ADSs will take place, (ii) the Company

shall not request the sale of any Placement ADSs and shall suspend or cancel any effective Placement Notices instructing the either Agent

to make any sales and (iii) the Agents shall not be obligated to sell or offer to sell any Placement ADSs.

5.            Settlement

and Delivery of the Placement ADSs.

(a)            Settlement

of Placement ADSs. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement ADSs will occur

on the first Trading Day following the date on which such sales are made(each, a “Settlement Date”). The amount

of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement ADSs sold (the “Net Proceeds”)

in U.S. Dollars and will be equal to the aggregate gross sales price received by the Agents at which such Placement ADSs were sold, after

deduction of (i) the Agents’ commission, discount or other compensation for such sales payable by the Company pursuant to Section 2

hereof, (ii) any other amounts due and payable by the Company to the Agents hereunder pursuant to Section 7(g) hereof and

(iii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.

(b)            Delivery

of Placement ADSs. On or before each Settlement Date, the Company will, or will cause the Depositary to, issue the Placement ADSs

being sold on such date and electronically transfer such Placement ADSs by crediting the Designated Agent’s or its designee’s

account (provided the Designated Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The

Depository Trust Company through its Deposit and Withdrawal at Custodian System (“DWAC”) or by such other means

of delivery as may be mutually agreed upon by the parties hereto, which in all cases shall be duly authorized, freely tradeable, transferable,

registered ADSs in good deliverable form. On each Settlement Date, the Designated Agent will deliver the related Net Proceeds in same

day funds to an account designated by the Company on or prior to the Settlement Date. The Designated Agent shall be responsible for providing

DWAC instructions or other instructions for delivery by other means with regard to the transfer of the Placement ADSs being sold. In addition

to and in no way limiting the rights and obligations set forth in Section 9(a) hereto, the Company agrees that if the Company

or the Depositary, defaults in its obligation to deliver duly authorized, freely tradeable, transferable, registered Placement ADSs in

good deliverable form by 2:30 P.M., New York City time, on a Settlement Date (other than as a result of a failure by the Designated Agent

to provide instructions for delivery), the Company will (i) take all necessary action to cause the full amount of any Net Proceeds

that were delivered to the Company’s account with respect to such settlement, together with any costs incurred by the Designated

Agent and/or its clearing firm in connection with recovering such Net Proceeds, to be immediately returned to the Designated Agent or

its clearing firm no later than 5:00 P.M., New York City time, on such Settlement Date, by wire transfer of immediately available

funds to an account designated by the Designated Agent or its clearing firm, (ii) indemnify and hold the Designated Agent and its

clearing firm harmless against any loss, claim, damage, or expense (including reasonable and documented legal fees and expenses), as incurred,

arising out of or in connection with such default by the Company or the Depositary and (iii) pay to the Designated Agent (without

duplication) any commission, discount or other compensation to which it would otherwise have been entitled absent such default. Certificates

for the Placement ADSs, if any, shall be in such denominations and registered in such names as the Designated Agent may request in writing

one Business Day (as defined below) before the applicable Settlement Date.

on Offering Size. Under no circumstances shall the Company cause or request the offer or sale of any Placement ADSs if, after giving

effect to the sale of such Placement ADSs, the aggregate number or gross sales proceeds of Placement ADSs sold pursuant to this Agreement

would exceed the lesser of: (i) the number or dollar amount of ADSs registered pursuant to, and available for offer and sale under,

the Registration Statement pursuant to which the offering of Placement ADSs is being made, (ii) the number of authorized but unissued

shares of ADSs of the Company (less Ordinary Shares, including any Ordinary Shares underlying ADSs, issuable upon exercise, conversion

or exchange of any outstanding securities of the Company or otherwise reserved from the Company’s authorized share capital), (iii) the

number or dollar amount of securities permitted to be offered and sold by the Company under Form S-3 (including General Instruction

I.B.6. thereof, if such instruction is applicable), (iv) the number or dollar amount of ADSs that the Company’s board of directors

(the “Board”) or a duly authorized committee thereof is authorized to issue and sell from time to time, and

notified to the Designated Agent in writing, or (v) the dollar amount of ADSs for which the Company has filed the ATM Prospectus.

Under no circumstances shall the Company cause or request the offer or sale of any Placement ADSs pursuant to this Agreement at a price

lower than the minimum price authorized from time to time by the Board or a duly authorized committee thereof, and notified to the Designated

Agent in writing. Notwithstanding anything to the contrary contained herein, the parties hereto acknowledge and agree that compliance

with the limitations set forth in this Section 5(c) on the number or dollar amount of Placement ADSs that may be issued and

sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agents shall have no obligation

in connection with such compliance.

(d)            Sales

through Agents. With respect to the offering and sale of Placement ADSs pursuant to this Agreement, the Company agrees that any offer

to sell Placement ADSs, any solicitation of an offer to buy Placement ADSs, and any sales of Placement ADSs shall only be effected by

or through a single Agent on any single given day, and the Company shall in no event request that more than one Agent offer or sell Placement

ADSs pursuant to this Agreement on the same day.

6.            Representations

and Warranties of the Company. The Company represents and warrants to, and agrees with, the Agents that, as of the date of this Agreement,

and as of (i) each Representation Date (as defined in Section 7(m)), (ii) each date on which a Placement Notice is given,

(iii) the date and time of each sale of any Placement ADSs pursuant to this Agreement and (iv) each Settlement Date (each such

time or date referred to in clauses (i) through (iv), an “Applicable Time”):

(a)            The

Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3

(including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement is an automatic shelf registration

statement under Rule 405 and was filed with the Commission and declared effective by the Commission under the Securities Act prior

to the issuance of any Placement Notices by the Company. At the time the Registration Statement became effective, the Company met the

then-applicable requirements for use of Form S-3 (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration

Statement meets, and the offering and sale of Placement ADSs as contemplated hereby comply with, the requirements of Rule 415(a)(1)(x) under

the Securities Act. The Agents are named as the agents engaged by the Company in the section entitled “Plan of Distribution”

in the ATM Prospectus. The Company has not received, and has no notice from the Commission of, any notice pursuant to Rule 401(g)(1) under

the Securities Act objecting to the use of the shelf registration statement form. No stop order of the Commission preventing or suspending

the use of the base prospectus, the ATM Prospectus or the Prospectus, or the effectiveness of the Registration Statement, has been issued,

and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission. At the time

of the initial filing of the Registration Statement, the Company paid the required Commission filing fees relating to the securities covered

by the Registration Statement, including the Placement ADSs that may be sold pursuant to this Agreement, in accordance with Rule 457(o) under

the Securities Act. Copies of the Registration Statement, ATM Prospectus, the Prospectus, any such amendments or supplements to any of

the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this Agreement have been delivered,

or are available through EDGAR, to the Agents and their counsel.

(b)            Each

of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective, at each deemed effective

date with respect to the Agents pursuant to Rule 430B(f)(2) under the Securities Act and as of each Applicable Time, complied,

complies and will comply in all material respects with the requirements of the Securities Act and did not, does not and will not contain

any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements

therein not misleading, except that the representations and warranties set forth in this sentence do not apply to Agents’ Information

(as defined in Section 25). The Prospectus and any amendment or supplement thereto, when so filed with the Commission under Rule 424(b) under

the Securities Act, complied, complies and as of each Applicable Time will comply in all material respects with the requirements of the

Securities Act, and each ATM Prospectus, Prospectus or issuer free writing prospectus (or any amendments or supplements to any of the

foregoing) furnished to the Agents for use in connection with the offering of the Placement ADSs was identical to the electronically transmitted

copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. Neither the Prospectus nor

any amendment or supplement thereto, as of its date and as of each Applicable Time, included, includes or will include an untrue statement

of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light

of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this sentence

do not apply to Agents’ Information. Each Incorporated Document heretofore filed, when it was filed (or, if any amendment with respect

to any such document was filed, when such amendment was filed), conformed in all material respects with the requirements of the Exchange

Act and were filed on a timely basis with the Commission, and any further Incorporated Documents so filed and incorporated after the date

of this Agreement will be filed on a timely basis and, when so filed, will conform in all material respects with the requirements of the

Exchange Act; no such Incorporated Document when it was filed (or, if an amendment with respect to any such document was filed, when such

amendment was filed), contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein

or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and

no such Incorporated Document, when it is filed, will contain an untrue statement of a material fact or will omit to state a material

fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they

were made, not misleading.

the time of filing the Registration Statement and (ii) at the time of the execution of this Agreement (with such date being used

as the determination date for purposes of this clause (ii)), the Company was not and is not an “ineligible issuer” (as defined

in Rule 405), without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that

the Company be considered an ineligible issuer.

(d)            [Reserved].

(e)            Each

issuer free writing prospectus, if any, as of its issue date and as of each Applicable Time, did not, does not and will not include any

information that conflicted, conflicts or will conflict with the information contained in the Registration Statement or the Prospectus,

including any Incorporated Document deemed to be a part thereof that has not been superseded or modified. Each issuer free writing prospectus

that the Company has filed, or is required to file, pursuant to Rule 433 or that was prepared by or on behalf of or used by the Company

complies or will comply in all material respects with the requirements of the Securities Act.

(f)            The

Company has not distributed and, prior to the later to occur of each Settlement Date and completion of any Agent’s distribution

of the Placement ADSs under this Agreement, will not distribute any offering material in connection with the offering and sale of the

Placement ADSs other than the Registration Statement, the Prospectus or any Permitted Free Writing Prospectus (as defined below).

(g)            The

interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement and the

Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s

rules and guidelines applicable thereto.

(h)            The

Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of

the Exchange Act. The ADSs are registered pursuant to Section 12(b) of the Exchange Act and are listed on Nasdaq, and the Company

has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the ADSs under the Exchange

Act or delisting the ADSs from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating

such registration or listing. The Company is in compliance with the current listing standards of Nasdaq.

(i)            No

person (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) has the right to act as an underwriter

or as a financial advisor to the Company in connection with the offer and sale of the Placement ADSs hereunder, whether as a result of

the filing or effectiveness of the Registration Statement or the sale of the Placement ADSs as contemplated hereby or otherwise. Except

for the Agents and the Depositary, there is no broker, finder or other party that is entitled to receive from the Company or any of its

subsidiaries any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this Agreement.

(j)            The

Company has been duly incorporated and is validly existing as an exempted company in good standing under the laws of the jurisdiction

of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as

described in the Registration Statement and the Prospectus and to enter into and perform its obligations under this Agreement. The Company

is duly qualified as a foreign corporation to transact business and is in good standing (where such concept exists) in each jurisdiction

in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except

where the failure to so qualify or to be in good standing could not reasonably be expected to result in a Material Adverse Change. For

the purposes of this Agreement, “Material Adverse Change” shall mean any material adverse change, or any development

involving a prospective material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties,

operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business,

of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated

by this Agreement or perform its obligations hereunder.

(k)            Each

of the Company’s “subsidiaries” (for purposes of this Agreement, as defined in Rule 405 under the Securities Act)

has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership, limited liability

company or other entity, as applicable, in good standing (where such concept exists) under the laws of the jurisdiction of its incorporation

or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business

as described in the Registration Statement and the Prospectus. Each of the Company’s subsidiaries is duly qualified as a foreign

corporation, partnership or limited liability company, as applicable, to transact business and is in good standing (where such concept

exists) in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the

conduct of business, except where the failure to so qualify or to be in good standing could not reasonably be expected to result in a

Material Adverse Change. All of the issued and outstanding share capital or other equity or ownership interests of each of the Company’s

subsidiaries have been duly authorized and validly issued, duly paid in accordance with its respective articles of association or by laws,

partnership agreement or operating agreement or similar organizational documents, as applicable, and are nonassessable and are owned by

the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse

claim. None of the outstanding share capital or equity interest in any subsidiary was issued in

violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each

of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization

and are in full force and effect. The Company does not own or control, directly or indirectly, any corporation, association or

other entity other than the subsidiaries listed in Exhibit 21.1 of the Company’s most recent Annual Report on Form 10-K

filed with the Commission.

(l)            The

authorized, issued and outstanding share capital of the Company is as set forth in the Company’s annual report on Form 10-K

for the most recent fiscal year or, if later, the Company’s quarterly report on Form 10-Q for the most recent fiscal quarter,

as of the dates referred to therein (subject, in each case, to the issuance of Placement ADSs under this Agreement, the issuance of shares

of Ordinary Shares or ADSs upon exercise of share options and warrants disclosed as outstanding as of the date hereof in the Registration

Statement and the Prospectus and the grant of options under existing share option plans described in the Registration Statement and the

Prospectus). The share capital of the Company (including the Ordinary Shares and the ADSs) conforms in all material respects to the description

thereof contained in the Registration Statement and Prospectus. All of the issued share capital of the Company has been duly authorized

and validly issued, is fully paid and nonassessable and has been issued in compliance with all federal and state securities laws. None

of the outstanding Ordinary Shares or ADSs were issued in violation of any preemptive rights, rights of first refusal or other similar

rights to subscribe for or purchase securities of the Company. The form of certificates for the Ordinary Shares conform to the corporate

law of the jurisdiction of the Company’s incorporation and to any requirements of the Company’s organizational documents.

There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity

or debt securities convertible into or exchangeable or exercisable for, any share capital of the Company or any of its subsidiaries other

than those described in the Registration Statement and the Prospectus. The descriptions of the Company’s equity incentive plans

or arrangements, and the options or other rights granted thereunder, set forth in the Registration Statement and the Prospectus in all

material respects accurately and fairly present the information required to be shown with respect to such plans, arrangements, options

and rights.

(m)          The

Ordinary Shares have been duly authorized and, when allotted and issued, will be validly issued, fully paid and nonassessable and free

of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Ordinary Shares. The Ordinary

Shares may be freely deposited by the Company with the Depositary Custodian or its nominee against issuance of ADRs evidencing the Placement

ADSs, as contemplated by the Deposit Agreement. The Placement ADSs have been duly authorized for issuance and sale pursuant to this Agreement

and, when allotted, issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully

paid and nonassessable, and the issuance and sale of the Placement ADSs is not subject to any preemptive rights, rights of first refusal

or other similar rights to subscribe for or purchase the Placement ADSs. When issued and delivered by the Company against payment therefor

pursuant to this Agreement, the purchasers of the Placement ADSs issued and sold hereunder will acquire good, marketable and valid title

to such Placement ADSs, free and clear of all pledges, liens, security interests, charges, claims or encumbrances.

(n)          This

Agreement has been duly and validly authorized, executed and delivered by the Company and constitutes a valid and legally binding obligation

of the Company, enforceable against the Company in accordance with its terms, except as enforceability, including rights of indemnification,

may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting

creditors’ rights generally and by general principles of equity. This Agreement conforms in all material respects to the descriptions

thereof in the Registration Statement and the Prospectus.

(o)          The

Company is not and, after giving effect to the offering and sale of the Placement ADSs and the application of the proceeds thereof as

described in the Prospectus, will not be an “investment company” as defined in the Investment Company Act of 1940, as amended.

(p)          Neither

the Company nor any of its subsidiaries is in violation of its articles of association or by-laws, partnership agreement or operating

agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would

be in default) (“Default”) under any indenture, loan, credit agreement, note, lease, license agreement, contract,

franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or

agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or

by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an “Existing

Instrument”), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to result

in a Material Adverse Change. The Company’s execution, delivery and performance of this Agreement, consummation of the transactions

contemplated hereby, by the Deposit Agreement and by the Registration Statement and the Prospectus, and the issuance and sale of the Offered

ADSs (including the use of proceeds from the sale of the Placement ADSs as described in the Registration Statement and the Prospectus

under the caption “Use of Proceeds”) (i) have been duly authorized by all necessary corporate action and will not result

in any violation of the provisions of the articles of association or by-laws, partnership agreement or operating agreement or similar

organizational documents, as applicable, of the Company or any of its subsidiaries, (ii) will not conflict with or constitute a breach

of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge

or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other

party to, any Existing Instrument, except for such Defaults or a Debt Repayment Triggering Event as would not reasonably be expected,

individually or in the aggregate, to result in a Material Adverse Change, and (iii) will not result in any violation of any law,

administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries, except for such violations

as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change. No consent, approval, authorization

or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for

the Company’s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby, by

the Deposit Agreement and by the Registration Statement and the Prospectus, except such as have been obtained or made by the Company and

are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or

the Financial Industry Regulatory Authority, Inc. (“FINRA”). As used herein, a “Debt Repayment

Triggering Event” means any event or condition which gives, or with the giving of notice or lapse of time would give, the

holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require

the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.

(q)           Except

as otherwise disclosed in the Registration Statement and the Prospectus, subsequent to the respective dates as of which information is

given in the Registration Statement and the Prospectus: (i) there has been no Material Adverse Change; (ii) the Company and

its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including

without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity,

whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material,

individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions

not in the ordinary course of business; and (iii) there has not been any material decrease in the share capital or any material change

in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind

declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company’s

subsidiaries on any class of shares, or any repurchase or redemption by the Company or any of its subsidiaries of any class of shares.

(r)            There

are no persons (as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities Act) with registration or

other similar rights to have any equity or debt securities of the Company registered for sale under the Registration Statement or included

in the offering contemplated by this Agreement, except for such rights as have been duly waived in a writing previously furnished to the

Agents.

(s)            The

financial statements, filed with the Commission as a part of or otherwise incorporated by reference into the Registration Statement and

the Prospectus, together with the related schedules and notes thereto, present fairly, in all material respects, the consolidated financial

position of the Company and its subsidiaries as of the dates indicated and the results of their operations, changes in shareholders’

equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting

principles, as applied in the United States (“U.S. GAAP”), applied on a consistent basis throughout the periods

involved, except as may be expressly stated in the related notes thereto. No other financial statements (historical or pro forma) or supporting

schedules are required to be included in or incorporated by reference into the Registration Statement or the Prospectus. The other financial

data set forth in or incorporated by reference into each of the Registration Statement and the Prospectus fairly present, in all material

respects, the information set forth therein on a basis consistent with that of the audited financial statements contained in the Registration

Statement and the Prospectus. To the Company’s knowledge, no person who has been suspended or barred from being associated with

a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB,

has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial

data filed with the Commission as a part of the Registration Statement and the Prospectus.

(t)            There

is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the

knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could reasonably be expected,

individually or in the aggregate, to result in a Material Adverse Change. No material labor dispute with the employees of the Company

or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists

or, to the knowledge of the Company, is threatened or imminent.

(u)            The

Company and its subsidiaries have good and marketable title to all of the personal property and other assets reflected as owned in the

financial statements referred to in Section 6(s)above (or elsewhere in the Registration Statement and the Prospectus), in each case

free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property,

improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable

leases, with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real

property, improvements, equipment or personal property by the Company or such subsidiary. The Company and its subsidiaries do not own

any real property.

(v)            The

Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure

to be so in compliance could not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.

(w)            Ernst &

Young LLP, whose report on the consolidated financial statements of the Company is filed with the Commission as part of the Company’s

most recent annual report on Form 10-K filed with the Commission and incorporated by reference in the Registration Statement and

the Prospectus, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and

the rules of the Public Company Accounting Oversight Board (“PCAOB”), (ii) in compliance with the

applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and

(iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has

not requested such registration to be withdrawn. Ernst & Young LLP has not been engaged by the Company to perform any “prohibited

activities” or provided to the Company any “non-audit services” (as defined in Section 10A of the Exchange Act).

(x)            The

Company and its subsidiaries have filed all federal, state and foreign income and franchise tax returns or have properly requested extensions

thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or

penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings to the extent that failure

to file or pay would not reasonably be expected to result in a Material Adverse Change. The Company has made adequate charges, accruals

and reserves in the applicable financial statements referred to in Section 6(s) above in respect of all U.S. federal, state

and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not

been finally determined, except to the extent that failure to do so would not reasonably be expected to result in a Material Adverse Change.

No stamp duty, stamp duty reserve, registration, transfer or other similar taxes or duties (“Transfer Taxes”)

are payable in the Cayman Islands, the People’s Republic of China (the “PRC”); for the avoidance of doubt,

the PRC does not include the Hong Kong Special Administrative Region (“Hong Kong”), the Macau Special Administrative

Region and Taiwan) or Hong Kong by or on behalf of the Agents in connection with (i) the creation and issuance of the Ordinary Shares

by the Company in the manner contemplated by this Agreement and the Deposit Agreement; (ii) the delivery of the Ordinary Shares by

the Company to the Depositary Custodian in the manner contemplated by the Deposit Agreement, (iii) the issuance of the Placement

ADSs (or the ADRs evidencing the Placement ADSs) by the Depositary, and the delivery of the Placement ADSs (or the ADRs evidencing the

Placement ADSs) to or for the account of the Agents, in each case in the manner contemplated by this Agreement and the Deposit Agreement;

(iv) the initial sale and delivery by the Agents of the Placement ADSs (or the ADRs evidencing the Placement ADSs) to purchasers

thereof in the manner contemplated by this Agreement; or (v) the execution and delivery of this Agreement or the Deposit Agreement.

(y)            Each

of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts

and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not

limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction

and acts of vandalism and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability

claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance

coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or

appropriate to conduct its business as now conducted and at a cost that could not reasonably be expected, individually or in the aggregate,

to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it

has sought or for which it has applied.

(z)            The

Company and its subsidiaries possess such valid and current certificates, authorizations, exemptions, clearances, approvals, registrations

or permits issued by state, federal or foreign governmental or regulatory agencies or bodies necessary to the conduct of their respective

businesses as currently conducted and as described in the Registration Statement and the Prospectus (“Permits”),

except where failure to so possess would not reasonably be expected to, individually or in the aggregate, result in a Material Adverse

Change. Neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any

notice of proceedings relating to the revocation or modification of, or non-compliance with, any such Permit, and to the Company’s

knowledge, no event has occurred, which allows, or after notice or lapse of time would allow, revocation or termination thereof or would

result in any other material impairment of the rights of the holder of any such Permit, except in each case, where such limitation, suspension,

modification or revocation would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Change.

(aa)         Except

as described in the Registration Statement and the Prospectus, the Company and each of its subsidiaries make and keep accurate books and

records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are

executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to

permit preparation of financial statements in conformity with U.S. GAAP and to maintain accountability for assets; (iii) access to

assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability

for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and

(v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement

and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission's

rules and guidelines applicable thereto.

(bb)         The

Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange

Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries,

is made known to the Company’s principal executive officer and its principal financial officer by others within those entities,

particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been

evaluated by management of the Company for effectiveness as of the end of the Company’s most recent fiscal quarter; and (iii) are

effective in all material respects to perform the functions for which they were established. Since the end of the Company’s most

recent audited fiscal year, there have been no significant deficiencies or material weaknesses in the Company’s internal control

over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that

has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal

quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial

reporting.

(cc)         Neither

the Company nor any of its subsidiaries has taken, directly or indirectly, without giving effect to activities by the Agents, any action

designed to or that would reasonably be expected to cause or result in stabilization or manipulation of the price of the Placement ADSs

or of any “reference security” (as defined in Rule 100 of Regulation M under the Exchange Act (“Regulation

M”)) with respect to the Placement ADSs, whether to facilitate the sale or resale of the Placement ADSs or otherwise, and

has taken no action which would directly or indirectly violate Regulation M.

(dd)         Except

as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change: (i) neither the Company

nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy

or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent,

decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air,

surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating

to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum

or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution,

use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”);

(ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental

Laws and are each in compliance with their requirements; (iii) there are no pending or, to the Company’s knowledge, threatened

administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,

investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) there are

no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action,

suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating

to Hazardous Materials or any Environmental Laws. In the ordinary course of its business, the Company conducts a periodic review of the

effect of Environmental Laws on the business, operations and properties of the Company and its subsidiaries, in the course of which it

identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required

for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints

on operating activities and any potential liabilities to third parties). No facts or circumstances have come to the Company’s attention

that could result in costs or liabilities that could be expected, individually or in the aggregate, to result in a Material Adverse Change.

(ee)         The

Company and its subsidiaries and any “employee benefit plan” (as defined under the Employee Retirement Income Security Act

of 1974, as amended, and the regulations and published interpretations thereunder (collectively, “ERISA”)) established

or maintained by the Company, its subsidiaries or their “ERISA Affiliates” (as defined below) are in compliance in all material

respects with ERISA. “ERISA Affiliate” means, with respect to the Company or any of its subsidiaries, any member

of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended,

and the regulations and published interpretations thereunder (the “Code”) of which the Company or such subsidiary

thereof is a member. No “reportable event” (as defined under ERISA) has occurred or is reasonably expected to occur with respect

to any “employee benefit plan” established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates,

that would reasonably be expected to result in material liability to the Company or its subsidiaries. No “employee benefit plan”

established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such “employee benefit plan”

were terminated, would have any “amount of unfunded benefit liabilities” (as defined under ERISA) that would reasonably be

expected to result in material liability to the Company and its subsidiaries. Neither the Company, its subsidiaries nor any of their ERISA

Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination

of, or withdrawal from, any “employee benefit plan” or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each

employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to

be qualified under Section 401(a) of the Code is so qualified and, to the Company’s knowledge, nothing has occurred, whether

by action or failure to act, which would cause the loss of such qualification.

(ff)          There

is, and has been, no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such,

to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in

connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.

(gg)         Neither

the Company nor any of its subsidiaries nor, to the Company’s knowledge, any employee or agent of the Company or any of its subsidiaries,

has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of

any law or of the character required to be disclosed in the Registration Statement or the Prospectus.

(hh)         Neither

the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge

of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of

its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution,

gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer,

promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee,

including of any government-owned or controlled entity or public international organization, or any political party, party official, or

candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977,

as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law;

or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment,

kickback or other unlawful payment or benefit. The Company and its subsidiaries and, to the knowledge of the Company, the Company’s

affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures

designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. Neither the Company nor any

of its subsidiaries will use, directly or indirectly, the proceeds of the offering in furtherance of an offer, payment, promise to pay,

or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption

laws.

(ii)            The

operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping

and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the Bank Secrecy Act, as amended

by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act

of 2001 (USA PATRIOT Act), and the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder

and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively,

the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency,

authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending

or, to the knowledge of the Company, threatened.

(jj)            Neither

the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, any agent, affiliate

or other person acting on behalf of the Company or any of its subsidiaries is, or is owned or controlled by one or more persons that are,

currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department

of the Treasury (“OFAC”) or the U.S. Department of State, the United Nations Security Council, the European

Union, His Majesty’s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, “Sanctions”);

nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target

of comprehensive Sanctions (currently, the Crimea region of Ukraine, the non-government controlled areas of the Kherson and Zaporizhzhia

regions of Ukraine, the so-called Donetsk People’s Republic and the so-called Luhansk People’s Republic or any other region

of Ukraine identified pursuant to Executive Order 14065, Cuba, Iran, North Korea, and Syria) (collectively, the “Sanctioned

Countries”); and the Company will not directly or indirectly use the proceeds of the sale of the Placement ADSs, or lend,

contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the

purpose of financing or facilitating the activities of or business with any person, that at the time of such financing or facilitation,

is the subject or the target of Sanctions in violation of Sanctions, or in or involving any Sanctions Country or in any other manner that

will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor

or otherwise) of applicable Sanctions. Since inception, the Company and its subsidiaries have not engaged in and are not now knowingly

engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target

of Sanctions in violation of Sanctions or with any Sanctioned Country.

(kk)         (i) The

Company and its subsidiaries own or possess valid and enforceable licenses for the inventions, patent applications, patents, trademarks,

trade names, service names, copyrights, trade secrets and other intellectual property described in the Registration Statement and the

Prospectus as being owned or licensed by them or which are necessary or material for the conduct of their respective businesses as currently

conducted or as currently proposed to be conducted (collectively, “Intellectual Property”), and except as would

not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, to the Company’s knowledge,

the conduct of their respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect

with any such rights of others. The Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or

unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication.

Except as disclosed in the Registration Statement and the Prospectus and except as would not, individually or in the aggregate, reasonably

be expected to result in a Material Adverse Change, to the Company’s knowledge: (i) there are no third parties who have rights

to any Intellectual Property purported to be owned by the Company or its subsidiaries, except for customary reversionary rights of third-party

licensors with respect to such Intellectual Property that are disclosed in the Registration Statement and the Prospectus as licensed to

the Company or one or more of its subsidiaries; and (ii) there is no infringement, misappropriation, breach, default or other violation,

or the occurrence of any event that, with notice, the passage of time or both, would result in any of the foregoing, by any third parties

of any of the Intellectual Property. There is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or

claim by any third party: (A) challenging the Company’s rights in or to any Intellectual Property; (B) challenging the

validity, enforceability or scope of any Intellectual Property; or (C) asserting that the Company or any of its subsidiaries infringes

or otherwise violates, or would, upon the commercialization of any product or service described in the Registration Statement or the Prospectus

as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary

rights of any third party. Except as disclosed in the Registration Statement or the Prospectus, each of the Company and its subsidiaries

is the sole owner of the Intellectual Property owned by it and has the valid and enforceable right to use such Intellectual Property without

the obligation to obtain consent to sublicense and without a duty of accounting to co-owner, as applicable. Except as disclosed in the

Registration Statement or the Prospectus, neither the Company nor any of its subsidiaries is obligated to pay a material royalty, grant

a license or option, or provide other material consideration to any third party in connection with the Intellectual Property. Except as

would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries

have materially complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or

any subsidiary, and, to the Company’s knowledge, all such agreements are in full force and effect. The Company and its subsidiaries

have taken all commercially reasonable steps to protect, maintain and safeguard the Intellectual Property, including the execution of

appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees.

All employees, consultants, agents and contractors engaged in the development of Intellectual Property on behalf of the Company or any

of its subsidiaries have executed appropriate invention assignment agreements whereby such employees, consultants, agents and contractors

presently assign all of their right, title and interest in and to such Intellectual Property to the Company or the relevant subsidiary,

as applicable, and to the Company’s knowledge, no such agreement has been breached or violated. To the Company’s knowledge,

no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention

assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or

with a former employer where the basis of such violation relates to such employee’s employment with the Company. Except as would

not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change, the Company and its subsidiaries

have taken reasonable and customary actions to protect their rights in and prevent the unauthorized use and disclosure of material trade

secrets and confidential business information (including confidential source code, ideas, research and development information, know-how,

formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information,

financial, marketing and business data, customer and supplier lists and information, pricing and cost information, business and marketing

plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no such unauthorized

use or disclosure. None of the Company owned Intellectual Property or technology (including information technology and outsourced arrangements)

employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual

obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation

of the rights of any persons, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse

Change.

(ii) For purposes of this Agreement

“Owned Patents” means patents and patent applications owned or purported to be solely owned by, or exclusively

licensed to, the Company or any of its subsidiaries. The product candidates described in the Registration Statement and the Prospectus

as under development by the Company or any subsidiary fall within the scope of the claims of one or more Owned Patents. All Owned Patents

have been duly and properly filed and each issued patent is being diligently maintained and is valid and enforceable; neither the Company

nor any of its subsidiaries is aware of any facts that would preclude the issuance of a valid and enforceable patent on any pending patent

applications included as Owned Patents; to the knowledge of the Company, the Company, its subsidiaries and the parties prosecuting such

applications have complied with their duty of candor and disclosure to the U.S. Patent and Trademark Office (the “USPTO”),

and all such requirements in the relevant foreign patent authority having similar requirements as the case may be, in connection with

the Owned Patents; to the Company’s knowledge, there is no patent or patent application that contains claims that dominate or may

dominate (as such term is described in 35 U.S.C. §135 and 37 C.F.R. 41.100 to 41.208) with the issued or pending claims of any of

the Owned Patents. The Company and its subsidiaries are the sole and exclusive owner of all Owned Patents, and hold all right, title and

interest in and to such Owned Patents free and clear of all liens, encumbrances, defects or other restrictions, except as would not reasonably

be expected, individually or in the aggregate, to result in a Material Adverse Change; and the Company is not aware of any valid or bona

fide basis for a finding that any of the Owned Patents is unpatentable, invalid or unenforceable; and the Owned Patents are patentable,

valid and enforceable, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Change.

In connection with the Owned Patents, all relevant prior art references known to the Company or any of its subsidiaries (and, to the Company’s

knowledge, its and their respective directors, officers employees and agents) were disclosed or will be disclosed to the USPTO to the

extent required by and in accordance with 37 C.F.R. Section 1.56; all information submitted to the USPTO in such patent applications,

and in connection with the prosecution of such applications, was accurate in all material respects; and neither the Company nor, to the

Company’s knowledge, any other person made any material misrepresentations or concealed any material information from the USPTO

in such applications, or in connection with the prosecution of such applications, in violation of 37 C.F.R. Section 1.56.

(ll)            The

clinical and preclinical studies, tests and trials conducted by or on behalf of or sponsored by the Company or any of its subsidiaries,

or in which the Company or its subsidiaries have participated with respect to the Company’s product candidates, including, without

limitation, any such studies, tests or trials that are described in, or the results of which are referred to in, the Registration Statement

and the Prospectus were and, if still pending, are being conducted in all material respects in accordance with all applicable laws, rules,

and regulations to which they are subject, including without limitation all applicable Health Care Laws (as defined below); each description

of the results of such studies, tests or trials is accurate in all material respects, and the Company and its subsidiaries have no knowledge

of any other studies, tests or trials, the results of which are inconsistent with, or otherwise call into question, the results described

or referred to in the Registration Statement or the Prospectus; the Company and its subsidiaries have made all such filings and obtained

all such allowances or approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services

(“FDA”) or any committee thereof or from any other U.S. or foreign government regulatory agency, or health care

facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the conduct of such studies,

tests or trials; neither the Company nor any of its subsidiaries has received any written notice of, or correspondence from, any Regulatory

Agency requiring the termination, suspension or modification of any studies, tests or trials, other than ordinary course written communications

with respect to modifications in connection with the design and implementation of such tests or trials, and, to the Company’s knowledge,

there are no reasonable grounds for the same.

(mm)       The

Company and its subsidiaries are, and at all times have been, in compliance in all material respects with all applicable Health Care Laws.

For purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act

(21 U.S.C. Section 301 et seq.) and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign

health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil

False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C.

Sections 286, 287, 1349 and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act

of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the civil monetary penalties law (42 U.S.C. Section 1320a-7a),

the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable

laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for

Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010,

as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements

under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national,

supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations

promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any subsidiary has received

any FDA Form-483, written notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from any

court or arbitrator or governmental or regulatory authority alleging or asserting material non-compliance with any applicable Health Care

Laws or Licenses required by any such Health Care Laws. Neither the Company nor any of its subsidiaries has received written notice of

any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or

governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care

Laws nor, to the Company’s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration

or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms,

notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports,

documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the

date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its

subsidiaries is a party to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements, consent

decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the

Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or

debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is

subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment,

suspension, or exclusion.

(nn)         The

Company acknowledges and agrees that the Agents have informed the Company that the Agents may, to the extent permitted under the Securities

Act and the Exchange Act, purchase and sell ADSs for their own account while this Agreement is in effect; provided, that (i) no

such purchase or sales shall take place while a Placement Notice is in effect (except to the extent the Agents may engage in sales of

Placement ADSs purchased or deemed purchased from the Company as a “riskless principal” or in a similar capacity) and (ii) the

Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agents, except as may be otherwise agreed

by the Company and the Agents.

(oo)         The

Company is not a party to any agreement with an agent or underwriter for any other “at the market” or continuous equity transaction.

(pp)         All

of the information provided to the Agents or to counsel for the Agents by the Company, its counsel, its officers and directors and, to

the Company’s knowledge, the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection

with the offering of the Placement ADSs is true, complete and correct in all material respects and compliant with FINRA’s rules,

and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules is true, complete and correct

in all material respects.

(qq)         As

of the close of trading on Nasdaq on March 31, 2026, the aggregate market value of the outstanding voting and non-voting common equity

(as defined in Rule 405) of the Company held by persons other than affiliates of the Company (pursuant to Rule 144 of the Securities

Act, those that directly, or indirectly through one or more intermediaries, control, or are controlled by, or are under common control

with, the Company) (the “Non-Affiliate ADSs”), was approximately $2,497.2 million (calculated by multiplying

(x) the price at which the ADSs of the Company were last sold on Nasdaq on March 31, 2026 by (y) the number of Non-Affiliate

Shares outstanding March 31, 2026). The Company is not a shell company (as defined in Rule 405) and has not been a shell company

for at least 12 calendar months previously.

(rr)           Neither

the issuance, sale and delivery of the Placement ADSs nor the application of the proceeds thereof by the Company as described in the Registration

Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation

of such Board of Governors.

(ss)          Each

of the independent directors (or independent director nominees, once appointed, if applicable) named in the Registration Statement and

Prospectus satisfies the independence standards established by Nasdaq and, with respect to members of the Company’s audit committee,

the enhanced independence standards contained in Rule 10A-3(b)(1) promulgated by the Commission under the Exchange Act.

(tt)           Neither

the Company nor, to the Company’s knowledge, any of its affiliates (within the meaning of Rule 144 under the Securities Act)

has, prior to the date hereof, made any offer or sale of any securities which could be “integrated” (within the meaning of

the Securities Act) with the offer and sale of the Placement ADSs hereunder.

(uu)         Each

financial or operational projection or other “forward-looking statement” (as defined by Section 27A of the Securities

Act or Section 21E of the Exchange Act) contained in the Registration Statement or the Prospectus (i) was so included by the

Company in good faith and with reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other

applicable facts and circumstances and (ii) is accompanied by meaningful cautionary statements identifying those factors that could

cause actual results to differ materially from those in such forward-looking statement. No such statement was made with the knowledge

of an executive officer or director of the Company that it was false or misleading.

(vv)         There

are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required

to be described in the Registration Statement or the Prospectus that have not been described as required. The Company does not have any

outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of

the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.

(ww)       The

Company is not in or subject to a bankruptcy or insolvency proceeding in any jurisdiction.

(xx)          The

Company and the Depositary have prepared and filed with the Commission a registration statement relating to the ADSs on Form F-6

(No. 333-269454) (the “Form F-6”) and a related prospectus for registration under the Securities Act

of the ADSs, have filed such amendments thereto and such amended prospectuses as may have been required to the date hereof, and will file

such additional amendments thereto and such amended prospectuses as may hereinafter be required. The registration statement on Form F-6

for registration of the ADSs, as amended at the time it became effective (including by the filing of any post-effective amendments thereto),

and the prospectus included therein, as then amended are hereinafter called the “ADS Registration Statement.” The Form F-6

was declared effective under the Securities Act on February 2, 2023, and (i) no stop order preventing or suspending the effectiveness

of the ADS Registration Statement is in effect, and no proceedings for such purpose are pending before or, to the knowledge of the Company,

threatened by the Commission, (ii) the ADS Registration Statement complies and, as amended or supplemented, if applicable, will comply

in all material respects with the Securities Act and the applicable rules and regulations of the Commission thereunder, (iii) the

ADS Registration Statement, when it became effective, did not contain and, as amended or supplemented, if applicable, will not contain

any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein not misleading and (iv) all

of the Placement ADSs are registered pursuant to the ADS Registration Statement.

(yy)         The

Deposit Agreement has been duly authorized, executed and delivered by the Company and, assuming due authorization, execution and delivery

by the Depositary, constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms, except

as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization or similar laws relating to or affecting creditors’

rights generally or by general equitable principles. Upon due issuance by the Depositary of the ADRs evidencing the Placement ADSs against

the deposit of the Ordinary Shares in respect thereof in accordance with the provisions of the Deposit Agreement, such ADRs will be duly

and validly issued and the persons in whose names the ADRs are registered will be entitled to the rights specified therein and in the

Deposit Agreement. The issuance and sale of the Placement ADSs by the Company and the deposit of the Ordinary Shares with the Depositary

and the issuance of the ADRs evidencing the Ordinary Shares as contemplated by this Agreement and the Deposit Agreement will neither (i) cause

any holder of any Ordinary Shares or ADSs, securities convertible into or exchangeable or exercisable for Ordinary Shares or ADSs or options,

warrants or other rights to purchase Ordinary Shares or ADSs or any other securities of the Company to have any right to acquire any preferred

shares of the Company nor (ii) trigger any anti-dilution rights of any such holder with respect to such Shares, ADSs, securities,

options, warrants or rights. The Deposit Agreement and the ADRs conform in all material respects to each description thereof in the Registration

Statement and the Prospectus. Each holder of ADRs issued pursuant to the Deposit Agreement shall be entitled, subject to the Deposit Agreement,

to seek enforcement of its rights through the Depositary or its nominee registered as a representative of the holders of the ADRs in a

direct suit, action or proceeding against the Company.

(zz)         All

statistical, demographic and market-related data included in the Registration Statement or the Prospectus are based on or derived from

sources that the Company believes, after reasonable inquiry, to be reliable and accurate in all material respects. To the extent required,

the Company has obtained the written consent to the use of such data from such sources.

(aaa)       The

Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites,

applications, and databases over which it has control (collectively, “IT Systems”) are adequate for, and operate

and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries

as currently conducted, and, to the knowledge of the Company free and clear of all material bugs, errors, defects, trojan horses, time

bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical,

technical and administrative controls, policies, procedures, and safeguards designed to maintain and protect their confidential information

and the integrity, operation, redundancy and security of all IT Systems and data used in connection with their businesses, including all

personal and personally identifiable data (collectively, “Personal Data”). The Company and its subsidiaries

have implemented reasonable backup and disaster recovery technology. There have been no breaches, violations, outages or unauthorized

uses of or accesses to the IT Systems or Personal Data, except for those that have been remedied without material cost or liability or

the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. Neither the Company

nor its subsidiaries have been notified of, and each of them has no knowledge of, any event or condition that could result in, any breach,

violation, outage or unauthorized use of or access to same.

(bbb)       The

Company and its subsidiaries are, and has been for the preceding three years, in material compliance with all applicable state and federal

laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority,

external policies, and contractual obligations relating to the privacy and security of IT Systems and Personal Data, including the collection,

storage, transfer (including, without limitation, any transfer across national borders), processing and/or use of Personal Data and to

the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification (collectively, the

“Privacy Requirements”). To ensure compliance with the Privacy Requirements, the Company and its subsidiaries

have in place, materially complies with, and take appropriate steps reasonably designed to ensure compliance in all material respects

with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, and handling of

Personal Data (the “Policies”). The Company and its subsidiaries have at all times in the preceding three years

made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures

made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory

rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received

written notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Requirements,

or has knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting

or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Requirement; or

(iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Requirement. The execution,

delivery and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Privacy

Requirements.

(ccc)        Except

as provided by laws or statutes generally applicable to transactions of the type described in this Agreement, neither the Company nor

any of its respective properties, assets or revenues has any right of immunity under Cayman Islands law, the PRC law, New York law or

United States law, from any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding,

from set-off or counterclaim, from the jurisdiction of any Cayman Islands, PRC, New York state or United States federal court, from service

of process, attachment upon or prior judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other

legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court, with respect to its

obligations, liabilities or any other matter under or arising out of or in connection with this Agreement or the Deposit Agreement. To

the extent that the Company or any of its respective properties, assets or revenues may have or may hereafter become entitled to any such

right of immunity in any such court in which proceedings may at any time be commenced, the Company waives or will waive such right to

the extent permitted by law and has consented to such relief and enforcement as provided in Section 16 and Section 17 of this

Agreement.

(ddd)       Any

final and conclusive judgment for a fixed or readily calculable sum of money rendered by a New York state or federal court having jurisdiction

under its own domestic laws and recognized by the Cayman Islands courts as having jurisdiction (according to Cayman Islands conflicts

of laws principles and rules of Cayman Islands private international law at the time when proceedings were initiated) to give such

final judgment in respect of any suit, action or proceeding against the Company based upon this Agreement or the Deposit Agreement and

any instruments or agreements entered into for the consummation of the transactions contemplated herein and therein would be declared

enforceable against the Company, without re-examination or review of the merits of the cause of action in respect of which the original

judgment was given or re-litigation of the matters adjudicated upon, by the courts of the Cayman Islands, provided that the judgment

is not in respect of taxes, a fine or a penalty, and that it was not obtained in a manner and is not of a kind the enforcement of which

is contrary to the public policy of the Cayman Islands.

(eee)       The

issuance and sale of the Placement ADSs as contemplated hereby will not cause any holder of any ADSs or Ordinary Shares, securities convertible

into or exchangeable or exercisable for ADSs or Ordinary Shares or options, warrants or other rights to purchase ADSs or Ordinary Shares

or any other securities of the Company to have any right to acquire any preferred shares of the Company.

(fff)          Neither

the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of

the contracts or agreements referred to or described in the Registration Statement or Prospectus, and no such termination or non-renewal

has been threatened by the Company or any of its subsidiaries or, to the Company’s knowledge, any other party to any such contract

or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.

(ggg)       No

subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any

other distribution with respect to such subsidiary’s equity securities or from repaying to the Company or any other subsidiary of

the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from

transferring any property or assets to the Company or to any other subsidiary.

(hhh)       Except

as disclosed in the Registration Statement and the Prospectus, under current laws and regulations of the Cayman Islands, the PRC, Hong

Kong and any political subdivision thereof, all dividends and other distributions declared and payable on the Placement ADSs may be paid

by the Company to the holder thereof in United States dollars that may be converted into foreign currency and may be freely transferred

out of the Cayman Islands, the PRC and Hong Kong and all such payments made to holders thereof or therein who are non-residents of the

Cayman Islands, the PRC or Hong Kong will not be subject to income, withholding or other taxes under laws and regulations of the Cayman

Islands, the PRC or Hong Kong or any political subdivision or taxing authority thereof or therein without the necessity of obtaining any

governmental authorization in the Cayman Islands, the PRC and Hong Kong or any political subdivision or taxing authority thereof or therein.

(iii)           The

Company is aware of and has been advised as to, the content of the Rules on Mergers and Acquisitions of Domestic Enterprises by Foreign

Investors jointly promulgated by the Ministry of Commerce, the State-owned Assets Supervision and Administration Commission of the State

Council, the State Taxation Administration, the State Administration for Industry and Commerce, the China Securities Regulatory Commission

(“CSRC”) and the State Administration of Foreign Exchange of the PRC on August 8, 2006, as amended by the

Ministry of Commerce of the PRC on June 22, 2009 (together with any official clarification, guidance, interpretation or implementation

rules related thereto, the “M&A Rules”), in particular the relevant provisions thereof which purport

to require offshore special purpose vehicles (“SPVs”), controlled directly or indirectly by PRC companies or

individuals and formed for listing purposes through acquisitions of PRC domestic companies or assets in exchange for the shares of the

SPVs, to obtain the approval of the CSRC prior to the listing and trading of their securities on an overseas stock exchange. The issuance

and sale of the Placement ADSs and the Ordinary Shares represented thereby, the listing and trading of the Placement ADSs on Nasdaq and

the consummation of the transactions contemplated by this Agreement and the Deposit Agreement are not, and will not be as of the date

hereof or any Settlement Date adversely affected by the M&A Rules.

(jjj)           Each

of the Company and its subsidiaries that was incorporated outside of the PRC has complied with, and has taken all reasonable steps to

comply with and to ensure compliance by each of its shareholders, option holders, directors, officers and employees that is, or is directly

or indirectly owned or controlled by, a PRC resident or citizen with any applicable rules and regulations of the relevant PRC government

agencies (including but not limited to the Ministry of Commerce, the National Development and Reform Commission and the State Administration

of Foreign Exchange) relating to overseas investment by PRC residents and citizens (the “PRC Overseas Investment and Listing

Regulations”), including, without limitation, requesting each shareholder, option holder, director, officer and employee

that is, or is directly or indirectly owned or controlled by, a PRC resident or citizen to complete any registration and other procedures

required under applicable PRC Overseas Investment and Listing Regulations.

(kkk)        Each

of this Agreement and the Deposit Agreement is in proper form under the laws of the Cayman Islands for the enforcement thereof against

the Company; and to ensure the legality, validity, enforceability or admissibility into evidence in Cayman Islands of this Agreement and

the Deposit Agreement, it is not necessary that this Agreement or the Deposit Agreement be filed or recorded with any court or other authority

in the Cayman Islands or that any stamp or similar tax in the Cayman Islands be paid on or in respect of this Agreement, the Deposit Agreement

or any other documents to be furnished hereunder, except for nominal stamp duty if the documents are executed in or brought into the Cayman

Islands.

(lll)          The

choice of law of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of the Cayman Islands,

the PRC and Hong Kong and will be recognized and given effect to in any action brought before a court of competent jurisdiction in the

Cayman Islands, the PRC and Hong Kong, subject to the principles and conditions described under the section titled “Enforcement

of Civil Liabilities” in the Registration Statement and the Prospectus. The Company has the power to submit, and pursuant to Section 17

has, to the extent permitted by law, legally, validly, effectively and irrevocably submitted, to the jurisdiction of the Specified Courts

(as hereinafter defined).

(mmm)     No

holder of any of the Ordinary Shares or the Placement ADSs after the consummation of the transactions contemplated by this Agreement or

the Deposit Agreement is or will be subject to any personal liability in respect of any liability of the Company or its subsidiaries by

virtue only of its holding of any such Ordinary Shares or Placement ADSs; and, except as set forth in the Registration Statement and the

Prospectus, there are no material limitations on the rights of holders of the Ordinary Shares or the Placement ADSs who are not PRC residents

to hold, vote or transfer their securities.

(nnn)      The

indemnification and contribution provisions set forth in Section 9 do not contravene Cayman Islands law or PRC law or public policy.

(ooo)       Any

Company-derived statistical and market-related data included in the Registration Statement and Prospectus have been derived from the records

of the Company using systems and procedures which incorporate adequate safeguards to ensure that such data are complete, true and accurate

in all material respects and are not misleading; any third-party statistical and market-related data included in the Registration Statement

and Prospectus are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company

has obtained the written consent for the use of such data from such sources to the extent required.

(ppp)       The

Company and its subsidiaries are (i) not a “person of a country of concern”; or (ii) not engaged in any “covered

activity,” as these terms are defined in 31 C.F.R. Part 850, as implemented or revised from time to time. The Company and its

subsidiaries have no intention of becoming a “person of a country of concern” that engages in any “covered activity.”

Any certificate signed by any officer of the Company

and delivered to the Agents or its counsel in connection with the offering of the Placement ADSs shall be deemed a representation and

warranty by the Company, as to matters covered thereby, to the Agents.

7.             Covenants

of the Company. The Company covenants and agrees with the Agents that:

(a)            Registration

Statement Amendments. After the date of this Agreement and during any period in which the Prospectus relating to any Placement ADSs

is required to be delivered by the Agents under the Securities Act (including in circumstances where such requirement may be satisfied

pursuant to Rule 172 under the Securities Act or a similar rule); (i) the Company will notify the Agents promptly of the time

when any subsequent amendment to the Registration Statement, other than Incorporated Documents, has been filed with the Commission and/or

has become effective or any subsequent supplement to the Prospectus, other than Incorporated Documents, has been filed and of any request

by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information; (ii) the

Company will prepare and file with the Commission, promptly upon the Agents’ request, any amendments or supplements to the Registration

Statement or Prospectus that, in the Agents’ reasonable opinion, may be necessary or advisable in connection with the distribution

of the Placement ADSs by the Agents (provided, however, that the failure of the Agents to make such request shall not relieve the Company

of any obligation or liability hereunder, or affect the Agents’ right to rely on the representations and warranties made by the

Company in this Agreement and provided, further, that the only remedy the Agents shall have with respect to the failure by the Company

to make such filing (but without limiting the Agents’ rights under Section 9 hereof) will be to cease making sales under this

Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration

Statement or Prospectus, other than Incorporated Documents, relating to the Placement ADSs or a security convertible into or exchangeable

or exercisable for the Placement ADSs unless a copy thereof has been submitted to the Agents within a reasonable period of time before

the filing and the Agents have not reasonably objected thereto (provided, however, that the failure of the Agents to make such objection

shall not relieve the Company of any obligation or liability hereunder, or affect the Agents’ right to rely on the representations

and warranties made by the Company in this Agreement and provided, further, that the only remedy the Agents shall have with respect to

the Company’s making such filing notwithstanding the Agents’ objection (but without limiting the Agents’ rights under

Section 9 hereof) will be to cease making sales under this Agreement) and the Company will furnish to the Agents at the time of filing

thereof a copy of any Incorporated Document, except for those documents available via EDGAR; and (iv) the Company will cause each

amendment or supplement to the Prospectus, other than Incorporated Documents, to be filed with the Commission as required pursuant to

the applicable paragraph of Rule 424(b) of the Securities Act and, in the case of any Incorporated Document, to be filed with

the Commission as required pursuant to the Exchange Act, within the time period prescribed.

(b)            Notice

of Commission Stop Orders. The Company will advise the Agents, promptly after it receives notice or obtains knowledge thereof, of

the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of

the suspension of the qualification of the Placement ADSs for offering or sale in any jurisdiction or of the initiation or threatening

of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop

order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agents promptly after it receives

any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or for

additional information related to the offering of the Placement ADSs or for additional information related to the Registration Statement

or the Prospectus.

of Prospectus; Subsequent Changes. During any period in which the Prospectus relating to the Placement ADSs is required to be delivered

by the Agents under the Securities Act with respect to the offer and sale of the Placement ADSs (including in circumstances where such

requirement may be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will comply with all requirements

imposed upon it by the Securities Act, as from time to time in force, and will file on or before their respective due dates (taking into

account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be

filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange

Act. If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue

statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances

then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus

to comply with the Securities Act, the Company will promptly notify the Agents to suspend the offering of Placement ADSs during such period

and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct

such statement or omission or effect such compliance; provided, however, that the Company may delay the filing of any amendment or supplement

if there is no pending Placement Notice and, in the reasonable judgment of the Company, it is in the best interest of the Company to do

so, during which time the Agents shall be under no obligation to make any sales of Placement ADSs hereunder. If the Company has omitted

any information from the Registration Statement pursuant to Rule 430B under the Securities Act, it will use its reasonable best efforts

to comply with the provisions thereof and make all requisite filings with the Commission pursuant to said Rule 430B and to notify

the Agents promptly of all such filings if not available on EDGAR.

(d)            Listing

of Placement ADSs. During any period in which the Prospectus relating to the Placement ADSs is required to be delivered by the Agents

under the Securities Act with respect to the offer and sale of the Placement ADSs (including in circumstances where such requirement may

be satisfied pursuant to Rule 172 under the Securities Act or a similar rule), the Company will use its commercially reasonable efforts

to cause the Placement ADSs to be listed on Nasdaq. The Company will timely file with Nasdaq all material documents and notices required

by Nasdaq of companies that have or will issue securities that are traded on Nasdaq.

(e)            Delivery

of Registration Statement and Prospectus. The Company will furnish to the Agents and their counsel (at the expense of the Company)

copies of the Registration Statement, the Prospectus (including all Incorporated Documents) and all amendments and supplements to the

Registration Statement or Prospectus that are filed with the Commission during any period in which the Prospectus relating to the Placement

ADSs is required to be delivered under the Securities Act (including all Incorporated Documents filed with the Commission during such

period), in each case as soon as reasonably practicable and in such quantities as the Agents may from time to time reasonably request

and, at the Agents’ request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement

ADSs may be made; provided, however, that the Company shall not be required to furnish any document (other than the Prospectus)

to the Agents to the extent such document is available on EDGAR.

(f)            Earnings

Statement. The Company will make generally available to its security holders and to the Agents as soon as practicable, but in any

event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month

period that satisfies the provisions of Section 11(a) of and Rule 158 under the Securities Act; provided that the Company

will be deemed to have furnished such statement to its security holders and the Agents to the extent such statement has been filed on

EDGAR.

(g)           Expenses.

The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated in accordance with

the provisions of Section 11 hereunder, will pay all expenses incident to the performance of its obligations hereunder, including

expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto,

of the Prospectus and of each amendment and supplement thereto and of this Agreement and such other documents as may be required in connection

with the offering, purchase, sale, issuance or delivery of the Placement ADSs, (ii) the preparation, issuance, sale and delivery

of the Placement ADSs and any transfer or other similar taxes due or payable in connection therewith, (iii) the qualification of

the Placement ADSs under securities laws in accordance with the provisions of Section 7(aa) of this Agreement, including filing fees

(provided, however, that any fees or disbursements of counsel for the Agents in connection therewith shall be paid by the Agents except

as set forth in clauses (vii) and (viii) below), (iv) the printing and delivery to the Agents and their counsel of copies

of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection

with the listing or qualification of the Placement ADSs for trading on Nasdaq, (vi) the filing fees and expenses, if any, owed to

the Commission or FINRA and the fees and expenses of the Depositary for the Placement ADSs, (vii) the fees and associated expenses

of the Agents’ outside legal counsel for filings with the FINRA Corporate Financing Department in an amount not to exceed $15,000

(excluding FINRA filing fees referred to in clause (vi) above and in addition to the fees and disbursements referred to in clause

(viii) below), and (viii) the reasonable and documented fees and disbursements of the Agent’s outside legal counsel (A) in

an amount not to exceed $100,000 arising out of executing this Agreement and the Company’s delivery of the initial certificate pursuant

to Section 7(m), (B) in an amount not to exceed $25,000 in connection with each Representation Date (as defined below) on which

the Company is required to provide a certificate pursuant to Section 7(m) (in addition to the fees and associated expenses referred

to in clause (vii) above) and (C) $25,000 for each program “refresh” (filing of a new registration statement, prospectus,

or prospectus supplement relating to the Placement ADSs and/or an amendment of this Agreement).

(h)            Use

of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”

(i)             Notice

of Other Sales. Without the prior written consent of the Agents, the Company will not, directly or indirectly, offer to sell, sell,

contract to sell, grant any option to sell or otherwise dispose of any ADSs (other than the Placement ADSs offered pursuant to this Agreement),

Ordinary Shares or securities convertible into or exchangeable or exercisable for ADSs or Ordinary Shares, warrants or any rights to purchase

or acquire ADSs or Ordinary Shares during the period beginning on the fifth Trading Day immediately prior to the date on which any Placement

Notice is delivered to an Agent hereunder and ending on the second Trading Day immediately following the final Settlement Date with respect

to Placement ADSs sold pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale

of all Placement ADSs covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly

in any other “at the market offering” or continuous equity transaction offer to sell, sell, contract to sell, grant any option

to sell or otherwise dispose of any ADSs (other than the Placement ADSs offered pursuant to this Agreement), Ordinary Shares or securities

convertible into or exchangeable or exercisable for ADSs or Ordinary Shares, warrants or any rights to purchase or acquire ADSs or Ordinary

Shares prior to the later of the termination of this Agreement and the thirtieth day immediately following the final Settlement Date with

respect to Placement ADSs sold pursuant to such Placement Notice; provided, however, that such restrictions will not be

required in connection with the Company’s issuance or sale of (i) ADSs or Ordinary Shares, options to purchase ADSs or Ordinary

Shares, other securities under the Company’s existing equity incentive plans, or ADSs or Ordinary Shares issuable upon the exercise

of options or vesting of other securities, pursuant to any employee or director stock option or benefits plan, stock ownership plan or

dividend reinvestment plan (but not ADSs or Ordinary Shares subject to a waiver to exceed plan limits in its dividend reinvestment plan),

inducement award under Nasdaq rules or other compensation plan of the Company whether now in effect or hereafter implemented, (ii) ADSs

or Ordinary Shares issuable upon conversion of securities or the exercise of warrants, options or other rights in effect or outstanding,

and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent, (iii) ADSs or Ordinary Shares or

securities convertible into or exchangeable for ADSs or Ordinary Shares as consideration for mergers, acquisitions, joint ventures, collaborations,

licensing arrangements, manufacturing, distribution, marketing, supply, sponsored research, technology transfer or development or third

party service arrangements, other business combinations or strategic alliances occurring after the date of this Agreement which are not

issued for capital raising purposes, (iv) modification of any outstanding options, warrants or any rights to purchase or acquire

ADSs or Ordinary Shares that are disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and (v) Ordinary

Shares or ADSs withheld or sold to cover tax obligations in connection with the exercise of outstanding options or the vesting and settlement

of restricted share units or other equity awards, which outstanding options, restricted share units or other equity awards are disclosed

in filings by the Company available on EDGAR or otherwise in writing to the Agent.

(j)            Change

of Circumstances. The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice

or sell Placement ADSs, advise the Agents promptly after it shall have received notice or obtained knowledge of any information or fact

that would alter or affect in any material respect any opinion, certificate, letter or other document provided or required to be provided

to the Agents pursuant to this Agreement.

(k)            Due

Diligence Cooperation. During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted

by the Agents, its affiliates agents and counsel from time to time in connection with the transactions contemplated hereby, including

providing information and making available documents and senior corporate officers, during regular business hours and at the Company’s

principal offices, as the Agents may reasonably request.

(l)             Required

Filings Relating to Placement of Placement ADSs. The Company agrees that on or prior to such dates as the Securities Act shall require,

with respect to the Placement Shares, the Company will (i) file a prospectus supplement with the Commission under the applicable

paragraph of Rule 424(b) under the Securities Act, which prospectus supplement will set forth, within the relevant period, the

number or amount of Placement ADSs sold through the Agents, the Net Proceeds to the Company and the compensation payable by the Company

to the Agents with respect to such Placement ADSs, and (ii) deliver such number of copies of each such prospectus supplement to each

exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market; provided,

that, unless a prospectus supplement containing such information is required to be filed under the Securities Act, the requirement of

this Section 7(l) may be satisfied by Company’s inclusion in the Company’s Form 10-K or Form 10-Q, as

applicable, of the number or amount of Placement ADSs sold through the Agents, the Net Proceeds to the Company and the compensation payable

by the Company to the Agents with respect to such Placement ADSs during the relevant period.

(m)            Representation

Dates; Certificate. On or prior to the date on which the Company first delivers a Placement Notice pursuant to this agreement (the

“First Placement Notice Date”) and each time the Company:

(i)             amends

or supplements the Registration Statement or the Prospectus relating to the Placement ADSs (other than a prospectus supplement filed in

accordance with Section 7(l) of this Agreement) by means of a post-effective amendment, sticker or supplement but not by means

of incorporation of document(s) by reference into the Registration Statement or the Prospectus relating to the Placement ADSs;

(ii)            files

an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or

a material amendment to the previously filed Form 10-K);

(iii)           files

a quarterly report on Form 10-Q under the Exchange Act; or

(iv)           files

a current report on Form 8-K containing amended financial information (other than an earnings release that is “furnished”

pursuant to Item 2.02 or Item 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred

to in clauses (i) through (iv) shall be a “Representation Date”),

the Company shall furnish the Agents (but in the case of clause (iv) above

only if (1) a Placement Notice is pending or in effect and (2) the Agents request such certificate within three Business Days

after the filing of such Form 8-K with the Commission) with a certificate, in the form attached hereto as Exhibit 7(m) (modified,

as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented), within two Trading Days of

any Representation Date. The requirement to provide a certificate under this Section 7(m) shall be waived for any Representation

Date occurring at a time at which no Placement Notice is pending or in effect, or if a suspension is in effect with respect to any Placement

Notice, which waiver shall continue until the earlier to occur of (1) the date the Company delivers a Placement Notice hereunder

(which for such calendar quarter shall be considered a Representation Date) and (2) the next occurring Representation Date. Notwithstanding

the foregoing, if the Company subsequently decides to sell Placement ADSs following a Representation Date on which the Company relied

on the waiver referred to in the previous sentence and did not provide the Agents with a certificate under this Section 7(m), then

before the Company delivers a Placement Notice or the Agents sell any Placement ADSs pursuant thereto, the Company shall provide the Agents

with a certificate, in the form attached hereto as Exhibit 7(m), dated the date of such Placement Notice. Within two

Trading Days of each Representation Date, the Company shall have furnished to the Agents such further information, certificates and documents

as the Agents may reasonably request.

(n)            U.S.

Legal Opinions. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate

pursuant to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents

the written opinion and negative assurance letter of Cooley LLP, counsel to the Company, or such other counsel satisfactory to the Agent

(“Company Counsel”), in form and substance satisfactory to the Agents and their counsel, dated the date that

the opinion and negative assurance letter are required to be delivered, modified, as necessary, to relate to the Registration Statement

and the Prospectus as then amended or supplemented; provided, however, that in lieu of such opinion and negative assurance

letter for subsequent Representation Dates, Company Counsel may furnish the Agents with a letter to the effect that the Agents may rely

on a prior opinion or negative assurance letter delivered by such counsel under this Section 7(n) to the same extent as if it

were dated the date of such letter (except that statements in such prior opinion or negative assurance letter shall be deemed to relate

to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).

(o)            Cayman

Islands Legal Opinions. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a

certificate pursuant to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished

to the Agents the written opinion of Travers Thorp Alberga, Cayman Islands counsel to the Company, or such other counsel satisfactory

to the Agents (“Cayman Counsel”), in form and substance satisfactory to the Agents and their counsel, dated

the date that the opinion is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus

as then amended or supplemented; provided, however, that in lieu of such opinion for subsequent Representation Dates, Cayman

Counsel may furnish the Agents with a letter to the effect that the Agents may rely on a prior opinion delivered by such counsel under

this Section 7(o) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion

shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).

(p)            PRC

Legal Opinions. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate

pursuant to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents

the written opinion of Zhong Lun Law Firm, PRC counsel to the Company, or such other counsel satisfactory to the Agents (“PRC

Counsel”), in form and substance satisfactory to the Agents and their counsel, dated the date that the opinion is required

to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided,

however, that in lieu of such opinion for subsequent Representation Dates, PRC Counsel may furnish the Agents with a letter to

the effect that the Agents may reference a prior opinion delivered by such counsel under this Section 7(p) to the same extent

as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration

Statement and the Prospectus as amended or supplemented at such Representation Date).

(q)            Depositary

Legal Opinions. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate

pursuant to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents

the written opinion of Ziegler, Ziegler & Associates LLP, counsel to the Depositary, or such other counsel satisfactory to the

Agents (“Depositary Counsel”), in form and substance satisfactory to the Agents and their counsel, dated the

date that the opinion is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus

as then amended or supplemented; provided, however, that in lieu of such opinion for subsequent Representation Dates, Depositary

Counsel may furnish the Agents with a letter to the effect that the Agents may rely on a prior opinion delivered by such counsel under

this Section 7(q) to the same extent as if it were dated the date of such letter (except that statements in such prior opinion

shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).

(r)            Intellectual

Property Opinion. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate

pursuant to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents

the written opinion of Sheppard, Mullin, Richter & Hampton LLP, counsel for the Company with respect to intellectual property

matters, or such other intellectual property counsel satisfactory to the Agents (“Intellectual Property Counsel”),

in form and substance satisfactory to the Agents and its counsel, dated the date that the opinion letter is required to be delivered,

modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; provided, however,

that in lieu of such written opinion for subsequent Representation Dates, Intellectual Property Counsel may furnish the Agents with

a letter to the effect that the Agents may rely on a prior opinion letter delivered by such counsel under this Section 7(r) to

the same extent as if it were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed

to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).

(s)            Comfort

Letter. On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant

to Section 7(m) for which no suspension or waiver is applicable, the Company shall cause its independent registered public accounting

firm (and any other independent accountants whose report is included in the Registration Statement or the Prospectus) to furnish the Agents

letters (the “Comfort Letters”), dated the date the Comfort Letter is delivered, which shall meet the requirements

set forth in this Section 7(s); provided, that if requested by the Agents, the Company shall cause a Comfort Letter to be

furnished to the Agents within 10 Trading Days of the occurrence of any material transaction or event that necessitates the filing of

additional, pro forma, amended or revised financial statements (including any restatement of previously issued financial statements).

Each Comfort Letter shall be in form and substance satisfactory to the Agents and each Comfort Letter from the Company’s independent

registered public accounting firm shall (i) confirm that they are an independent registered public accounting firm within the meaning

of the Securities Act and the PCAOB, (ii) state, as of such date, the conclusions and findings of such firm with respect to the financial

information and other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection with

registered public offerings (the first such letter, the “Initial Comfort Letter”) and (iii) update the

Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date

and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such

letter.

(t)            On

or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to Section 7(m) for

which no waiver is applicable, the Company shall deliver to the Agents a certificate executed by the Chief Financial Officer of the Company

(“CFO Certificate”), dated as of such date, in form and substance satisfactory to the Agents.

(u)            Market

Activities. The Company will not, directly or indirectly, and will cause its officers, directors and subsidiaries not to (i) take

any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation

of the price of any security of the Company to facilitate the sale or resale of ADSs or Ordinary Shares or (ii) sell, bid for, or

purchase ADSs or Ordinary Shares in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement

ADSs other than the Agents; provided, however, that the Company may bid for and purchase ADSs or Ordinary Shares in accordance

with Rule 10b-18 under the Exchange Act.

(v)            Insurance.

The Company and its subsidiaries shall maintain, or cause to be maintained, insurance in such amounts and covering such risks as is reasonable

and customary for the business for which it is engaged.

(w)            Compliance

with Laws. The Company and each of its subsidiaries shall maintain, or cause to be maintained, all material environmental certificates,

authorizations or permits required by federal, state and local law in order to conduct their businesses as described in the Prospectus

(collectively, “Compliance Permits”), and the Company and each of its subsidiaries shall conduct their businesses,

or cause their businesses to be conducted, in substantial compliance with such Compliance Permits and with applicable Environmental Laws,

except where the failure to maintain or be in compliance with such Compliance Permits could not reasonably be expected to result in a

Material Adverse Change.

(x)            Investment

Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor any of its subsidiaries

will be or become, at any time prior to the termination of this Agreement, an “investment company,” as such term is defined

in the Investment Company Act.

(y)            Securities

Act and Exchange Act. The Company will use its reasonable best efforts to comply with all requirements imposed upon it by the Securities

Act and the Exchange Act as from time to time in force, so far as necessary to permit the sales of, or dealings in, the Placement ADSs

as contemplated by the provisions hereof and the Prospectus.

(z)            No

Offer to Sell. Other than a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by

the Company and the Agents, neither the Agents nor the Company (including its agents and representatives, other than the Agents in their

capacity as agents) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under

the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Placement

ADSs hereunder.

(aa)         Blue

Sky and Other Qualifications. The Company will use its commercially reasonable efforts, in cooperation with the Agents, to qualify

the Placement ADSs for offering and sale, or to obtain an exemption for the Placement ADSs to be offered and sold, under the applicable

securities laws of such states and other jurisdictions (domestic or foreign) as the Agents may designate and to maintain such qualifications

and exemptions in effect for so long as required for the distribution of the Placement ADSs (but in no event for less than one year from

the date of this Agreement); provided, however, that the Company shall not be obligated to file any general consent to service

of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or

to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise so subject. In each jurisdiction

in which the Placement ADSs have been so qualified or exempt, the Company will file such statements and reports as may be required by

the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect for so long as required for the

distribution of the Placement ADSs (but in no event for less than one year from the date of this Agreement).

(bb)         Sarbanes-Oxley

Act. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal accounting controls

in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial

statements for external purposes in accordance with U.S. GAAP and including those policies and procedures that (i) pertain to the

maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the

Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of the Company’s

financial statements in accordance with U.S. GAAP, (iii) that receipts and expenditures of the Company are being made only in accordance

with management’s and the Company’s directors’ authorization, and (iv) provide reasonable assurance regarding prevention

or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on

its financial statements. The Company will maintain such controls and other procedures, including, without limitation, those required

by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations thereunder that are designed to ensure that information

required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized

and reported, within the time periods specified in the Commission’s rules and forms, including, without limitation, controls

and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under

the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive officer and principal

financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and

to ensure that material information relating to the Company is made known to it by others within the Company, particularly during the

period in which such periodic reports are being prepared..

(cc)         [Reserved]

(dd)         Renewal

of Registration Statement. If, immediately prior to the third anniversary of the initial effective date of the Registration Statement

(the “Renewal Date”), any of the Placement ADSs remain unsold and this Agreement has not been terminated, the

Company, in its sole discretion, may, prior to the Renewal Date, file a new shelf registration statement or, if applicable, an automatic

shelf registration statement relating to the Placement ADSs that may be offered and sold pursuant to this Agreement (which shall include

a prospectus reflecting the number or amount of Placement ADSs that may be offered and sold pursuant to this Agreement), in a form satisfactory

to the Agent and their counsel, and, if such registration statement is not an automatic shelf registration statement, will use its reasonable

best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Date. The Company will take

all other reasonable actions necessary or appropriate to permit the public offer and sale of the Placement ADSs to continue as contemplated

in the expired registration statement and this Agreement. From and after the effective date thereof, references herein to the “Registration

Statement” shall include such new shelf registration statement or such new automatic shelf registration statement, as the case may

be.

(ee)         General

Instruction I.B.6. of Form S-3. If, from and after the date of this Agreement, the Company is no longer eligible to use Form S-3

(including pursuant to General Instruction I.B.6.) at the time it files with the Commission an annual report on Form 10-K or any

post-effective amendment to the Registration Statement, then it shall promptly notify the Agents and, within two Business Days after the

date of filing of such annual report on Form 10-K or amendment to the Registration Statement, the Company shall file a new prospectus

supplement with the Commission reflecting the number of ADSs available to be offered and sold by the Company under this Agreement pursuant

to General Instruction I.B.6. of Form S-3; provided, however, that the Company may delay the filing of any such prospectus

supplement for up to 30 days if, in the reasonable judgment of the Company, it is in the best interest of the Company to do so, provided

that no Placement Notice is in effect or pending during such time. Until such time as the Company shall have corrected such misstatement

or omission or effected such compliance, the Company shall not notify the Agents to resume the offering of Placement ADSs.

(ff)           Tax

Indemnity. The Company will indemnify and hold harmless the Agents against any documentary, stamp or similar issue tax, including

any interest and penalties, on the issue and sale of the Placement ADSs.

(gg)         Depositary.

The Company has engaged and will maintain, at its sole expense, a depositary for the ADSs.

8.             Conditions

to the Agents’ Obligations. The obligations of the Agents hereunder with respect to a Placement will be subject to the continuing

accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its

obligations hereunder, to the completion by the Agents of a due diligence review satisfactory to the Agents in their reasonable judgment,

and to the continuing satisfaction (or waiver by the Agents in their sole discretion) of the following additional conditions:

(a)            Registration

Statement Effective. The Registration Statement shall be effective and shall be available for all offers and sales of Placement ADSs

(i) that have been issued pursuant to all prior Placement Notices and (ii) that will be issued pursuant to any Placement Notice.

(b)            ATM

Prospectus. The Company shall have filed with the Commission the ATM Prospectus pursuant to Rule 424(b) under the Securities

Act not later than the Commission’s close of business on the second Business Day following the date of this Agreement.

Material Notices. None of the following events shall have occurred and be continuing: (i) receipt by the Company or any of its

subsidiaries of any request for additional information from the Commission or any other federal or state governmental authority during

the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements

to the Registration Statement or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority

of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt

by the Company or any of its subsidiaries of any notification with respect to the suspension of the qualification or exemption from qualification

of any of the Placement ADSs for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the

occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material Incorporated

Document untrue in any material respect or that requires the making of any changes in the Registration Statement, the Prospectus or Incorporated

Documents so that, in the case of the Registration Statement, it will not contain any untrue statement of a material fact or omit to state

any material fact required to be stated therein or necessary to make the statements therein not misleading and, in the case of the Prospectus,

so that it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or

necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(d)            No

Misstatement or Material Omission. The Agents shall not have advised the Company that the Registration Statement or Prospectus, or

any amendment or supplement thereto, contains an untrue statement of fact that in the Agents’ opinion is material, or omits to state

a fact that in the Agents’ opinion is material and is required to be stated therein or is necessary to make the statements therein

not misleading.

(e)            Material

Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the Commission, there shall

not have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse

Change or any development that could reasonably be expected to result in a Material Adverse Change, or any downgrading in or withdrawal

of the rating assigned to any of the Company’s securities (other than asset backed securities), if any, by any rating organization

or a public announcement by any rating organization that it has under surveillance or review its rating of any of the Company’s

securities (other than asset backed securities), if any, the effect of which, in the judgment of the Agents (without relieving the Company

of any obligation or liability it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering

of the Placement ADSs on the terms and in the manner contemplated in the Prospectus.

(f)            Company

Counsel Legal Opinions. The Agent shall have received the opinions and negative assurance letters, as applicable, of Company Counsel,

Cayman Counsel, PCR Counsel, Depositary Counsel and Intellectual Property Counsel required to be delivered pursuant to Section 7(n) and

Section 7(o), as applicable, on or before the date on which such delivery of such opinions and negative assurance letters are required

pursuant to Section 7(n), Section 7(o), Section 7(p), Section 7(q) and Section 7(r), as applicable.

(g)            Agents’

Counsel Legal Opinion. The Agents shall have received from Latham & Watkins LLP, counsel for the Agents, such opinion or

opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to Section 7(n),

with respect to such matters as the Agents may reasonably require, and the Company shall have furnished to such counsel such documents

as they may request to enable them to pass upon such matters.

(h)            Comfort

Letter. The Agents shall have received the Comfort Letter required to be delivered pursuant to Section 7(s) on or before

the date on which such delivery of such Comfort Letter is required pursuant to Section 7(s).

(i)             Representation

Certificate. The Agents shall have received the certificate required to be delivered pursuant to Section 7(m) on or before

the date on which delivery of such certificate is required pursuant to Section 7(m).

(j)             Secretary’s

Certificate. On or prior to the First Placement Notice Date, the Agents shall have received a certificate, signed on behalf of the

Company by the Secretary of the Company and attested to by an executive officer of the Company, dated as of such date and in form and

substance satisfactory to the Agents and their counsel, certifying as to (i) the amended and restated memorandum and articles of

association, (ii) the resolutions of the Board or duly authorized committee thereof authorizing the execution, delivery and performance

of this Agreement and the issuance and sale of the Placement ADSs and the issuance of the Ordinary Shares represented by such ADSs and

(iii) the incumbency of the officers of the Company duly authorized to execute this Agreement and the other documents contemplated

by this Agreement (including each of the officers set forth on Schedule 2).

(k)            CFO

Certificate. The Agents shall have received the CFO Certificate required to be delivered pursuant to Section 7(m) on or

before the date on which delivery of such CFO Certificate is required to pursuant to Section 7(m).

(l)             No

Suspension. The ADSs shall be duly listed, and admitted and authorized for trading, subject to official notice of issuance, on Nasdaq.

Trading in the ADSs shall not have been suspended on, and the ADSs shall not have been delisted from, Nasdaq.

(m)           Other

Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(m), the Company shall

have furnished to the Agents such appropriate further information, opinions, certificates, letters and other documents as the Agents may

have reasonably requested. All such information, opinions, certificates, letters and other documents shall have been in compliance with

the provisions hereof. The Company shall have furnished the Agents with conformed copies of such opinions, certificates, letters and other

documents as the Agents may have reasonably requested.

(n)           Securities

Act Filings Made. All filings with the Commission required by Rule 424(b) or Rule 433 under the Securities Act to have

been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for

such filing by Rule 424(b) (without reliance on Rule 424(b)(8) of the Securities Act) or Rule 433, as applicable.

(o)           Approval

for Listing. The Placement ADSs shall have been approved for listing on Nasdaq.

(p)           FINRA.

FINRA shall have raised no objection to the terms of the offering contemplated hereby and the amount of compensation allowable or payable

to the Agents as described in the Prospectus.

(q)           No

Termination Event. There shall not have occurred any event that would permit the Agents to terminate this Agreement pursuant to Section 11(a).

(r)            Deposit

Agreement. The Deposit Agreement shall be in full force and effect and the Company and the Depositary shall have taken all action

necessary to permit the deposit of Ordinary Shares underlying the Placement ADSs and the issuance of the Placement ADSs in accordance

with the Deposit Agreement.

9.             Indemnification

and Contribution.

(a)            Company

Indemnification. The Company agrees to indemnify and hold harmless each Agent, its affiliates and their respective partners, members,

directors, officers, employees and agents, and each person, if any, who (i) controls an Agent within the meaning of Section 15

of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with an Agent, in

each case from and against any and all losses, claims, liabilities, expenses and damages (including any and all investigative, legal and

other expenses reasonably incurred in connection with, and any and all amounts paid in settlement (in accordance with this Section 9),

any action, suit, investigation or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified

party and any third party (including any governmental or self-regulatory authority, or otherwise, or any claim asserted or threatened),

as and when incurred, to which such Agent, or any such other person may become subject under the Securities Act, the Exchange Act or other

federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages

arise out of or are based, directly or indirectly, on (x) any untrue statement or alleged untrue statement of a material fact contained

in the Registration Statement or the Prospectus (or any amendment or supplement to the Registration Statement or the Prospectus) or in

any free writing prospectus or in any application or other document executed by or on behalf of the Company or based on written information

furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Ordinary Shares or Placement ADSs under the

securities laws thereof or filed with the Commission, (y) the omission or alleged omission to state in any such document a material

fact required to be stated therein or necessary to make the statements therein (solely with respect to the Prospectus, in light of the

circumstances under which they were made) not misleading or (z) any breach by any of the indemnifying parties of any of their respective

representations, warranties or agreements contained in this Agreement; provided, however, that this indemnity agreement

shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement ADSs pursuant

to this Agreement and is caused, directly or indirectly, by an untrue statement or omission, or alleged untrue statement or omission,

made in reliance upon and in conformity with the Agents’ Information. This indemnity agreement will be in addition to any liability

that the Company might otherwise have.

(b)            Agent

Indemnification. Each Agent agrees, severally but not jointly, to indemnify and hold harmless the Company and its directors and each

officer of the Company who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning

of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control

with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 9(a),

as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration

Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) or in any free writing prospectus in

reliance upon and in conformity with the Agents’ Information.

Any party that proposes to assert the right to be indemnified under this Section 9 will, promptly after receipt of notice of commencement

of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section 9,

notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission so to

notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified

party otherwise than under this Section 9 and (ii) any liability that it may have to any indemnified party under the foregoing

provision of this Section 9 unless, and only to the extent that, such omission results in the forfeiture of substantive rights or

defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party

of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering written

notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly

with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the

indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying

party will not be liable to the indemnified party for any other legal expenses except as provided below and except for the reasonable

costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have

the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense

of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying

party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available

to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict

or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying

party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified

party) or (4) the indemnifying party has not in fact employed counsel reasonably satisfactory to the indemnified party to assume

the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the

reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood

that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be

liable for the reasonable fees, disbursements and other charges of more than one separate firm (plus local counsel) admitted to practice

in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be

reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to such fees, disbursements

and other charges in reasonable detail. An indemnifying party will not, in any event, be liable for any settlement of any action or claim

effected without its written consent. No indemnifying party shall, without the prior written consent of each indemnified party, settle

or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters

contemplated by this Section 9 (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent

(1) includes an unconditional release of each indemnified party, in form and substance reasonably satisfactory to such indemnified

party, from all liability arising out of such claim, action or proceeding and (2) does not include a statement as to or an admission

of fault, culpability or a failure to act by or on behalf of any indemnified party.

(d)            Settlement

Without Consent if Failure to Reimburse. If an indemnified party shall have requested an indemnifying party to reimburse the

indemnified party for reasonable fees and expenses of counsel for which it is entitled to be reimbursed under this Section 9, such

indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by Section 9(a) effected without

its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid

request, (ii) such indemnifying party shall have received notice of the terms of such settlement at least 30 days prior to such settlement

being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance with such request

prior to the date of such settlement.

(e)            Contribution.

In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs

of this Section 9 is applicable in accordance with its terms but for any reason is held to be unavailable or insufficient from the

Company or the Agents, the Company and the Agents will contribute to the total losses, claims, liabilities, expenses and damages (including

any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action,

suit, investigation or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other

than the Agents, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed

the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and each Agent

may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and

each Agent on the other hand. The relative benefits received by the Company on the one hand and each Agent on the other hand shall be

deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement ADSs (before deducting expenses) received

by the Company bear to the total compensation received by each Agent from the sale of Placement ADSs on behalf of the Company. If, but

only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be

made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the

relative fault of the Company, on the one hand, and the applicable Agent, on the other hand, with respect to the statements or omission

that resulted in such loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in respect thereof, as well

as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to,

among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material

fact relates to information supplied by the Company or the applicable Agent, the intent of the parties and their relative knowledge, access

to information and opportunity to correct or prevent such statement or omission. The Company and the Agents agree that it would not be

just and equitable if contributions pursuant to this Section 9(e) were to be determined by pro rata allocation or by

any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable

by an indemnified party as a result of the loss, claim, liability, expense or damage, or action, suit, investigation or proceeding in

respect thereof, referred to above in this Section 9(e) shall be deemed to include, for the purpose of this Section 9(e),

any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action,

suit, investigation, proceeding or claim to the extent consistent with this Section 9. Notwithstanding the foregoing provisions of

this Section 9(e), the no Agent shall not be required to contribute any amount in excess of the commissions received by it under

this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities

Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 9(e),

any person who controls a party to this Agreement within the meaning of Section 15 of the Securities Act or Section 20 of the

Exchange Act, any affiliates of an Agent, any partners, members, directors, officers, employees and agents of an Agent and each person

that is controlled by or under common control with an Agent will have the same rights to contribution as that party, and each officer

and director of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in

each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action

against such party in respect of which a claim for contribution may be made under this Section 9(e), will notify any such party or

parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution

may be sought from any other obligation it or they may have under this Section 9(e) except to the extent that the failure to

so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except

for a settlement entered into pursuant to the last sentence of Section 9(c) hereof or pursuant to Section 9(d) hereof,

no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required

pursuant to Section 9(c) hereof. For the avoidance of doubt, the Agents’ respective obligations to contribute pursuant

to this Section 9(e) are several in proportion to the respective number of Placement ADSs they have sold hereunder, and not

joint.

10.            Representations

and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 9 of this Agreement and all

representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective

dates, regardless of (i) any investigation made by or on behalf of either Agent, any controlling persons, or the Company (or any

of their respective officers, directors, employees or controlling persons), (ii) delivery and acceptance of the Placement ADSs and

payment therefor or (iii) any termination of this Agreement.

11.           Termination.

(a)            Each

Agent shall have the right, with respect to itself, by giving notice as hereinafter specified, at any time to terminate this Agreement

if (i) any Material Adverse Change, or any development that could reasonably be expected to result in a Material Adverse Change,

has occurred that, in the judgment of such Agent, may materially impair the ability of the Agent to sell the Placement ADSs hereunder,

(ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; provided,

however, in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion or

letter required under Section 7(m), Section 7(n), Section 7(o), Section 7(p), Section 7(q), Section 7(r),

Section 7(s) or Section 7(t), such Agent’s right to terminate shall not arise unless such failure to deliver (or

cause to be delivered) continues for more than 15 calendar days from the date such delivery was required, (iii) any other condition

of such Agent’s obligations hereunder is not fulfilled, (iv) any suspension or limitation of trading in the Placement ADSs

or in securities generally on Nasdaq shall have occurred, (v) a general banking moratorium shall have been declared by any of United

States federal or New York authorities, or (vi) there shall have occurred any outbreak or escalation of national or international

hostilities or any crisis or calamity, or any change in the United States or international financial markets, or any substantial change

or development involving a prospective substantial change in United States or international political, financial or economic conditions

that, in the judgment of such Agent, may materially impair the ability of such Agent to sell the Placement ADSs hereunder or to enforce

contracts for the sale of securities. Any such termination shall be without liability of any party to any other party except that the

provisions of Section 7(g), Section 9, Section 10, Section 16 and Section 17 hereof shall remain in full force

and effect notwithstanding such termination. If an Agent elects to terminate this Agreement as provided in this Section 11(a), such

Agent shall provide the required notice as specified in Section 12. For the avoidance of doubt, the termination by one Agent of its

rights and obligations under this Agreement pursuant to this Section 11(a) shall not affect the rights and obligations of the

other Agent under this Agreement.

(b)            The

Company shall have the right, by giving 10 days’ prior notice as hereinafter specified, to terminate this Agreement in its sole

discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party

except that the provisions of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17

hereof shall remain in full force and effect notwithstanding such termination.

Agent shall have the right, by giving 10 days’ prior notice as hereinafter specified, to terminate this Agreement, with respect

to such Agent’s rights and obligations under this Agreement, in its sole discretion at any time after the date of this Agreement.

Any such termination shall be without liability of any party to any other party except that the provisions of Section 7(g), Section 9,

Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in full force and effect notwithstanding

such termination. For avoidance of doubt, the termination by one Agent of its rights and obligations under this Agreement pursuant to

this Section 11(c) shall not affect the rights and obligations of the other Agent under this Agreement.

(d)           Unless

earlier terminated pursuant to this Section 11, this Agreement shall automatically terminate upon the issuance and sale of all of

the Placement ADSs through the Agents on the terms and subject to the conditions set forth herein; provided that the provisions

of Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17 hereof shall remain in

full force and effect notwithstanding such termination.

(e)            This

Agreement shall remain in full force and effect unless terminated pursuant to Sections 11(a), (b), (c), or (d) above or otherwise

by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases

be deemed to provide that Section 7(g), Section 9, Section 10, Section 11(f), Section 16 and Section 17

shall remain in full force and effect.

(f)            Any

termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such

termination shall not be effective until the close of business on the date of receipt of such notice by the Agents or the Company, as

the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement ADSs, such Placement ADSs shall

settle in accordance with the provisions of this Agreement. Upon termination of this Agreement, the Company shall not be required to pay

to an Agent any discount or commission with respect to any Placement ADSs not otherwise sold by such Agent under this Agreement; provided,

however, that the Company shall remain obligated to reimburse such Agent’s expenses pursuant to Section 7(g).

12.            Notices.

All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement

shall be in writing, unless otherwise specified in this Agreement, and shall be delivered to:

if to Leerink Partners LLC, to:

Leerink Partners LLC

1301 Avenue of the Americas, 5th Floor

New York, New York 10019

Attention: Peter M. Fry

E-mail: [***]@leerink.com

with a copy (which shall not constitute notice) to:

Leerink Partners LLC

1301 Avenue of the Americas, 5th Floor

New York, New York 10019

Attention: Legal Department

E-mail:

[***]@leerink.com

if to Cantor Fitzgerald & Co., to:

Cantor Fitzgerald & Co.

110 East 59th Street

New York, NY 10022

Attention: Capital Markets

Facsimile:

[***]

with a copy to:

Cantor Fitzgerald & Co.

110 East 59th Street

New York, NY 10022

Attention: General Counsel

Facsimile:

[***]

in the case of notices to either or both of Leerink Partners LLC and

Cantor Fitzgerald & Co., with a copy to:

Latham & Watkins LLP

12670 High Bluff Drive

San Diego, CA 92130

Attention: Cheston Larson; Matt Bush

and if to the Company, shall be delivered to:

Structure Therapeutics Inc.

611 Gateway Ave, Suite 900

South San Francisco, CA 94080

Attention: Raymond Stevens, Ph.D.

with copies (which shall not constitute notice) to:

Cooley LLP

10265 Science Center Drive

San Diego, CA 92121-1909

Attention: Patrick Loofbourrow; Carlos Ramirez;

and Charlie Kim

Each party to this Agreement may change such address for notices by

sending to the parties to this Agreement written notice of a new address for such purpose. Each such notice or other communication shall

be deemed given (i) when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not

a Business Day, on the next succeeding Business Day, (ii) by Electronic Notice as set forth in the next paragraph, (iii) on

the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv) on the Business Day actually received

if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement,

“Business Day” shall mean any day on which the Nasdaq and commercial banks in the City of New York are open

for business.

An electronic communication (“Electronic Notice”)

shall be deemed written notice for purposes of this Section 12 if sent to the electronic mail address specified by the receiving

party in Section 12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives actual acknowledgment

of receipt from the person whom the notice is sent, other than via auto-reply. Any party receiving Electronic Notice may request and shall

be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic Notice”), which shall be

sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.

13.            Successors

and Assigns. This Agreement shall inure to the benefit of and be binding upon the Company and each Agent and their respective successors

and the affiliates, controlling persons, officers, directors and other persons referred to in Section 9 hereof. References to any

of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of each such party. Nothing

in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto, the persons referred to in

the preceding sentence and their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or

by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under

this Agreement without the prior written consent of the other party; provided, however, that each Agent may assign its rights and

obligations hereunder to an affiliate of such Agent without obtaining the Company’s consent, so long as such affiliate is a registered

broker-dealer.

14.            Adjustments

for Share Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to

take into account any share split, share dividend or similar event effected with respect to the Ordinary Shares and any change in exchange

ratio or similar event effected with respect to the ADSs.

15.            Entire

Agreement; Amendment; Severability; Waiver. This Agreement (including all schedules (as amended pursuant to this Agreement) and exhibits

attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous

agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof (including, for

the avoidance of doubt, the Original Sales Agreement). Neither this Agreement nor any term hereof may be amended except pursuant to a

written instrument executed by the Company and the Agents; provided, however, that Schedule 2 of this Agreement

may be amended by either party from time to time by sending a notice containing a revised Schedule 2 to the other party

in the manner provided in Section 12 and, upon such amendment, all references herein to Schedule 2 shall automatically

be deemed to refer to such amended Schedule 2. In the event that any one or more of the provisions contained herein, or

the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction,

then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the

remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not

contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall

be in accordance with the intent of the parties as reflected in this Agreement. No implied waiver by a party shall arise in the absence

of a waiver in writing signed by such party. No failure or delay in exercising any right, power, or privilege hereunder shall operate

as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of

any right, power, or privilege hereunder.

16.            GOVERNING

LAW AND TIME; WAIVER OF JURY TRIAL. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF

NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH PARTY HEREBY

IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING

OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

17.            Consent

to Jurisdiction; Waiver of Immunity; Service of Process.

(a)             Each

party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough

of Manhattan (the “Specified Courts”), for the adjudication of any dispute hereunder or in connection with any

of the transactions contemplated hereby (“Related Proceedings”), and hereby irrevocably waives, and agrees not

to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such

suit, action or proceeding is brought in an inconvenient forum, or that the venue of such suit, action or proceeding is improper. Each

party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding

by mailing a copy (certified or registered mail, return receipt requested) to such party at the address in effect for notices under Section 12

of this Agreement and agrees that such service shall constitute good and sufficient notice of process and notice thereof. Nothing contained

herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.

(b)            With

respect to any Related Proceeding, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether

on the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution

to which it might otherwise be entitled in the Specified Courts, and will not raise or claim or cause to be pleaded any such immunity

at or in respect of any such Related Proceeding, including, without limitation, any immunity pursuant to the United States Foreign Sovereign

Immunities Act of 1976, as amended.

Company irrevocably appoints Raymond Stevens, Ph.D., in his capacity as Chief Executive Officer, and any successor thereto, at Structure

Therapeutics Inc., located at 611 Gateway Blvd., Suite 900, South San Francisco, California 94080, as its authorized agent upon which

process may be served in any Related Proceeding, and agrees that service of process upon such authorized agent, and written notice of

such service to the Company, as the case may be, by the person serving the same to the address provided in this Section, shall be deemed

in every respect effective service of process upon the Company in any such suit or proceeding. The Company hereby represents and warrants

that such authorized agent has accepted such appointment and has agreed to act as such authorized agent for service of process. The Company

further agrees to take any and all action as may be necessary to maintain such designation and appointment of such authorized agent in

full force and effect.

18.            Construction.

(a)            The

section and exhibit headings herein are for convenience only and shall not affect the construction hereof.

(b)            Words

defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

words “hereof,” “hereto,” “herein” and “hereunder” and words of similar import, when used

in this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement.

(d)            Wherever

the word “include,” “includes” or “including” is used in this Agreement, it shall be deemed to be

followed by the words “without limitation.”

(e)             References

herein to any gender shall include each other gender.

(f)             References

herein to any law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority shall be deemed

to refer to such law, statute, ordinance, code, regulation, rule or other requirement of any governmental authority as amended, reenacted,

supplemented or superseded in whole or in part and in effect from time to time and also to all rules and regulations promulgated

thereunder.

19.            Permitted

Free Writing Prospectuses. Each of the Company and the Agents represent, warrant and agree that, unless it obtains the prior written

consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not make

any offer relating to the Placement ADSs that would constitute an issuer free writing prospectus, or that would otherwise constitute a

free writing prospectus (as defined in Rule 405), required to be filed with the Commission. Any such free writing prospectus consented

to by the Agents or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”

The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an issuer

free writing prospectus, and that it has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free

Writing Prospectus, including timely filing with the Commission where required, legending and record keeping.

20.            Absence

of Fiduciary Relationship. The Company acknowledges and agrees that:

(a)            each

Agent has been retained to act as a sales agent in connection with the sale of the Placement ADSs, each Agent has acted at arms’

length and no fiduciary or advisory relationship between the Company or any of its respective affiliates, stockholders (or other equity

holders), creditors or employees or any other party, on the one hand, and such Agent, on the other hand, has been or will be created in

respect of any of the transactions contemplated by this Agreement, irrespective of whether such Agent has advised or is advising the Company

on other matters and such Agent has no duties or obligations to the Company with respect to the transactions contemplated by this Agreement

except the obligations expressly set forth herein;

(b)            the

Company is capable of evaluating, and understanding and understands and accepts, the terms, risks and conditions of the transactions contemplated

by this Agreement;

the Agents nor their respective affiliates have provided any legal, accounting, regulatory or tax advice with respect to the transactions

contemplated by this Agreement and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed

appropriate;

(d)            the

Company has been advised and is aware that the Agents and their affiliates are engaged in a broad range of transactions which may involve

interests that differ from those of the Company and that the Agents and their affiliates have no obligation to disclose such interests

and transactions to the Company by virtue of any fiduciary, advisory or agency relationship or otherwise; and

(e)            the

Company waives, to the fullest extent permitted by law, any claims it may have against the Agents or their affiliates for breach of fiduciary

duty or alleged breach of fiduciary duty in connection with the transactions contemplated by this Agreement and agrees that the Agents

and their affiliates shall have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any

person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders (or other equity holders), creditors

or employees of the Company.

21.            Recognition

of the U.S. Special Resolution Regimes. In the event that an Agent is a Covered Entity and becomes subject to a proceeding under a

U.S. Special Resolution Regime, the transfer from such Agent of this Agreement, and any interest and obligation in or under this Agreement,

will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and

any such interest and obligation, were governed by the laws of the United States or a state of the United States.

In the event that an Agent is a Covered Entity

and such Agent or a BHC Act Affiliate of such Agent becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights

under this Agreement that may be exercised against such Agent are permitted to be exercised to no greater extent than such Default Rights

could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state

of the United States.

For purposes of this Agreement, (A) “BHC

Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12

U.S.C. § 1841(k); (B) “Covered Entity” means any of the following: (i) a “covered entity” as that

term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); (ii) a “covered bank” as that term

is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is

defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned

to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S.

Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and

(ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

22.            Counterparts.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall

constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or electronic

transmission. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal

ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com)

or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and

effective for all purposes.

23.            Use

of Information.         The Agents may not provide any information gained in connection with this Agreement

and the transactions contemplated by this Agreement, including due diligence, to any third party other than its legal counsel advising

it on this Agreement and the transactions contemplated by this Agreement unless expressly approved by the Company in writing.

24.            Judgment

Currency. The obligations of the Company pursuant to this Agreement in respect of any sum due to any Agent shall, notwithstanding

any judgment in a currency other than United States dollars, not be discharged until the first business day following receipt by any Agent

of any sum adjudged to be so due in such other currency, on which such Agent may in accordance with normal banking procedures purchase

United States dollars with such other currency. If the United States dollars so purchased are less than the sum originally due to such

Agent in United States dollars hereunder, the Company agrees as a separate obligation and notwithstanding any such judgment, to indemnify

such Agent against such loss. If the United States dollars so purchased are greater than the sum originally due to such Agent hereunder,

such Agent agrees to pay to the Company an amount equal to the excess of the United States dollars so purchased over the sum originally

due to such Agent hereunder.

All

payments made by the Company under this Agreement, if any, will be made without withholding or deduction for or on account of any present

or future taxes, duties, assessments or governmental charges of whatever nature (other than taxes on net income) imposed or levied by

or on behalf of the Cayman Islands or the PRC or any political subdivision or any taxing authority thereof or therein unless the Company

is or becomes required by law to withhold or deduct such taxes, duties, assessments or other governmental charges. In such event, the

Company will pay such additional amounts as will result, after such withholding or deduction, in the receipt by each Agent and each person

controlling any Agent, as the case may be, of the amounts that would otherwise have been receivable in respect thereof.

25.            Agents’

Information. As used in this Agreement, “Agents’ Information” means, with respect to an Agent, solely

the following information in the Registration Statement and the Prospectus: (i) with respect to each Agent, the name and address

of such Agent and (ii) the last sentence of the seventh paragraph under the heading “Plan of Distribution” in the ATM

Supplement as such sentence relates to such Agent.

All references in this Agreement to the Registration

Statement, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission

pursuant to EDGAR. All references in this Agreement to financial statements and schedules and other information that is “contained,”

“included” or “stated” in the Registration Statement or the Prospectus (and all other references of like import)

shall be deemed to mean and include all such financial statements and schedules and other information that is incorporated by reference

in the Registration Statement or the Prospectus, as the case may be.

All

references in this Agreement to “supplements” to the Prospectus shall include any supplements, “wrappers” or similar

materials prepared in connection with any offering, sale or private placement of any Placement ADSs by the Agents outside of the

United States.

[Remainder of Page Intentionally Blank]

the foregoing correctly sets forth the understanding between the Company and the Agents, please so indicate in the space provided

below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agents.

Very truly yours,

STRUCTURE THERAPEUTICS INC.

By:

/s/ Raymond Stevens

Name: Raymond Stevens, Ph.D.

Title: Chief Executive Officer

ACCEPTED as of the date

first-above written:

LEERINK PARTNERS LLC

By:

/s/ Peter Fry

Name: Peter Fry

Title: Head of Alt Equities

CANTOR FITZGERALD &

CO.

By:

/s/ Sameer Vasudev

Name: Sameer Vasudev

Title: Managing Director

SCHEDULE 1

FORM OF PLACEMENT NOTICE

From:

[ ]

[TITLE]

Structure Therapeutics Inc.

Cc:

[ ]

To:

Leerink Partners LLC

Subject:

Leerink Partners —At the Market Offering—Placement Notice

Ladies and Gentlemen:

Pursuant to the terms and subject to the conditions contained in the

Amended and Restated Sales Agreement, dated May 7 ,2026 (as amended and restated, the “Agreement”), by

and among Structure Therapeutics Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (the

“Company”), Leerink Partners LLC (“Leerink Partners”) and Cantor Fitzgerald &

Co. (“Cantor”), I hereby request on behalf of the Company that [ ], as Designated Agent, sell up to [ ]

American Depositary Shares, each representing 3 ordinary shares, $0.0001 par value per ordinary share, of the Company (the “ADSs”),

at a minimum market price of $ per share[; provided that no more than [ ] ADSs shall be sold in any

one Trading Day (as such term is defined in Section 3 of the Agreement)]. Sales should begin [on the date of this Placement Notice]

and end on [DATE] [until all ADSs that are the subject of this Placement Notice are sold].

SCHEDULE 2

The Company

[***]

Leerink Partners

[***]

Cantor Fitzgerald & Co.

[***]

SCHEDULE 3

Compensation

The Company

shall pay the Designated Agent compensation in cash up to 3% of the gross proceeds from the sales of Placement ADSs pursuant to

the terms of the Sales Agreement of which this Schedule 3 forms a part.

Exhibit 7(m)

OFFICERS’ CERTIFICATE

Each of Raymond

Stevens, Ph.D., the duly qualified and elected Chief Executive Officer of Structure Therapeutics Inc., an exempted company with

limited liability incorporated under the laws of the Cayman Islands (the “Company”), and Jun Yoon, the duly

qualified and elected Chief Financial Officer of the Company, does hereby certify in his respective capacity and on behalf of the Company,

pursuant to Section 7(m) of the Amended and Restated Sales Agreement, dated May 7, 2026 (the “Sales Agreement”),

by and among the Company, Leerink Partners LLC, and Cantor Fitzgerald & Co. that, after due inquiry, to the best of the knowledge

of the undersigned:

(i)            The

representations and warranties of the Company in Section 6 of the Sales Agreement (A) to the extent such representations and

warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Change, are true

and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, and (B) to

the extent such representations and warranties are not subject to any qualifications or exceptions relating to materiality or Material

Adverse Change, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same

force and effect as if expressly made on and as of the date hereof.

(ii)            The

Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement

at or prior to the date hereof.

(iii)            As

of the date hereof, (A) the Registration Statement complies in all material respects with the requirements of the Securities Act

and does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary

in order to make the statements therein not misleading, (B) the Prospectus complies in all material respects with the requirements

of the Securities Act does not contain any untrue statement of a material fact or omit to state a material fact required to be stated

therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading

and (C) no event has occurred as a result of which it is necessary to amend or supplement the Registration Statement or the Prospectus

in order to make the statements therein not untrue or misleading or for clauses (A) and (B) above, to be true and correct.

(iv)            There

has been no Material Adverse Change, or any development that could reasonably be expected to result in a Material Adverse Change, in the

condition (financial or otherwise), earnings, results of operations, business, properties, operations, assets, liabilities or prospects

of the Company and its subsidiaries, taken as a whole, whether or not arising from transactions in the ordinary course of business, since

the date as of which information is given in the Prospectus, as amended or supplemented to the date hereof.

(v)            The

Company does not possess any material non-public information.

(vi)            The

maximum amount of Placement ADSs that may be sold pursuant to the Sales Agreement has been duly authorized by the Company’s board

of directors or a duly authorized committee thereof pursuant to a resolution or unanimous written consent in accordance with the Company’s

amended and restated articles of incorporation, amended and restated bylaws and applicable law.

Capitalized terms used but not defined herein shall

have the meanings ascribed to them in the Sales Agreement.

Cooley LLP and Latham & Watkins LLP are

entitled to rely on this certificate in connection with the respective opinions such firms are rendering pursuant to the Sales Agreement.

IN WITNESS WHEREOF, each of the undersigned, in

such individual’s respective capacity as Chief Executive Officer or Chief Financial Officer of the Company, has executed this Officers’

Certificate on behalf of the Company.

By:

Name: Raymond Stevens, Ph.D.

Title: Chief Executive Officer

Date:

By:

Name: Jun Yoon

Title: Chief Financial Officer

Date:

[Company Signature Page to Officers’

Certificate]

EX-5.1 — EXHIBIT 5.1

EX-5.1

Filename: tm2613721d1_ex5-1.htm · Sequence: 3

Exhibit 5.1

Structure Therapeutics Inc.

Harbour Place, 2nd Floor, North Wing

103 South Church Street

P.O. Box 472, George Town

Grand Cayman KY1-1106

Cayman Islands

7 May 2026

Structure Therapeutics Inc.

We have acted as Cayman Islands legal advisers

to Structure Therapeutics Inc. (the "Company") in connection with the offering by the Company of American Depositary

Shares ("ADSs") representing certain of its ordinary shares, par value US$0.0001 per share (the "Placement Shares"),

having an aggregate offering price of up to US$400,000,000, pursuant to the Registration Statement on Form S-3 (File No. 333-278969)

(the "Registration Statement") filed with the United States Securities and Exchange Commission (the "Commission")

under the United States Securities Act of 1933, as amended (the "Act"), the sales agreement prospectus relating to the

Placement Shares included in the Registration Statement (the "Sales Agreement Prospectus"), and the prospectus supplement

filed with the Commission pursuant to Rule 424(b) under the Act on or about May 7, 2026 (together with the Sales Agreement

Prospectus, the "ATM Prospectus"). The ADSs representing Placement Shares are to be sold by the Company in accordance

with the Sales Agreement, dated 6 August 2025, by and between the Company, Leerink Partners LLC, and Cantor Fitzgerald &

Co. (as amended, the "Sales Agreement"), as described in the ATM Prospectus.

1 Documents Reviewed

For the purposes of this opinion, we have reviewed

originals, copies, drafts or conformed copies of the documents listed in Schedule 1 to this opinion, being all of the documents necessary

to form our opinion. Defined terms shall have the meanings set out in Schedule 1 or in the Registration Statement.

2 Assumptions

The following opinions are given only as to and

based on circumstances and matters of fact existing at the date hereof and as to the laws of the Cayman Islands as the same are in force

at the date hereof. In giving this opinion, we have relied upon the completeness and accuracy (and assumed the continuing completeness

and accuracy as at the date hereof) of the Director's Certificate, as to matters of fact, without further verification and have assumed

that copy documents or drafts of documents provided to us are true and complete copies of, or in the final forms of, the originals.

3 Opinions

Based upon, and subject to, the foregoing assumptions,

and having regard to such legal considerations as we deem relevant, we are of the opinion that:

3.1 the Company has been duly incorporated and is validly existing and in good standing under the laws of

the Cayman Islands;

3.2 as of the date of this opinion, the authorized share capital of the Company is US$60,000 divided into

500,000,000 Ordinary Shares of a par value of US$0.0001 each, and 100,000,000 shares of a par value of US$0.0001 each of such class or

classes (however designated) as the Board may determine in accordance with Article 9 of the Seventh Amended and Restated Memorandum

and Articles of Association;

3.3 the issue and allotment of the Placement Shares have been duly authorized and when allotted, issued and

paid for as contemplated in the Sales Agreement, the Placement Shares will be legally issued and allotted, fully paid and non-assessable.

In this opinion, the phrase "non-assessable" means, with respect to Placement Shares, that a shareholder shall not, solely by

virtue of its status as a shareholder, in the absence of a contractual arrangement to the contrary, be liable for additional assessments

or calls on the Placement Shares by the Company or its creditors (except in exceptional circumstances, such as involving fraud, the establishment

of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift

the corporate veil). As a matter of Cayman Islands law, a share is only issued when it has been entered in the register of members (shareholders);

and

3.4 the statements under the caption "Taxation" in the ATM Prospectus forming part of the Registration

Statement, to the extent that they constitute statements of Cayman Islands law, are accurate in all material respects and such statements

constitute our opinion.

We hereby consent to the filing of this opinion

as an exhibit to the Company’s Current Report on Form 8-K to be filed with the Commission for incorporation by reference into

the Registration Statement (the “Form 8-K”). In providing our consent, we do not thereby admit that we are in

the category of persons whose consent is required under Section 7 of the Act or the Rules and Regulations of the Commission

thereunder.

This opinion is limited to the matters detailed

herein and is not to be read as an opinion with respect to any other matter.

Yours faithfully

/s/ TRAVERS THORP ALBERGA

TRAVERS THORP ALBERGA

SCHEDULE 1

List of Documents Reviewed

1 the Certificate of Incorporation dated 27 February 2019 and the Certificate of Incorporation on Change

of Name dated 1 July 2022;

2 the register of members of the Company;

3 the register of directors of the Company;

4 the Seventh Amended and Restated Memorandum and Articles of Association of the Company as adopted by a

special resolution dated 19 January 2023;

5 the resolutions of the Board of Directors of the Company (the "Board") dated 5 August 2025

(the "Board Resolutions");

6 the resolutions of the pricing committee of the Board (the "Pricing Committee") dated

on or about the date of this opinion (the "Pricing Committee Resolutions");

7 a certificate of good standing of the Company issued by the Registrar of Companies, Cayman Islands (the

"Certificate of Good Standing");

8 a certificate from a Director of the Company addressed to this firm, a copy of which is attached hereto

(the "Director's Certificate");

9 the Registration Statement (including the ATM Prospectus); and

10 the Form 8-K.

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613721d1_ex99-1.htm · Sequence: 4

Exhibit 99.1

Structure Therapeutics

Reports First Quarter 2026 Financial Results and Recent Highlights

Reported positive results

from aleniglipron Phase 2 ACCESS II study

with up to 16.3%

body weight loss, demonstrating highest efficacy among oral GLP-1RAs

at the 44-week

time point and potentially comparable efficacy to injectable GLP1-RAs

Data from ACCESS

OLE expected in Q3 2026;

Data from the Body Composition

and Type 2 Diabetes / Obesity data expected in Q4 2026

Positive end-of-Phase 2 feedback received from FDA;

aleniglipron

Phase 3 initiation on track for Q3 2026

Initial data

from Phase 1 single ascending dose (SAD) study of oral small molecule amylin

receptor agonist

ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in

Q3 2026; Phase

1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026

Aleniglipron,

amylin and combination data to be presented

at the American

Diabetes Association (ADA) 86th Scientific Sessions in June 2026

Cash, cash equivalents

and short-term investments of $1.5 billion as of March 31, 2026,

expected to provide

cash runway through the end of 2028

SAN FRANCISCO, May 7, 2026–

Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule

therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31,

2026, and provided a business update.

“With positive end of Phase 2

feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight

management in the third quarter,” said Raymond Stevens, Ph.D., CEO of Structure Therapeutics. “We are also looking forward to our aleniglipron

presentation along with presentations on our oral amylin and GLP-1 combination program at the upcoming ADA meeting. With our Phase

1 clinical data for our oral amylin candidate ACCG-2671 anticipated in the third quarter and additional aleniglipron data later this year, our broad

portfolio positions us well in the evolving landscape that we believe will favor more accessible oral small molecules, extended maintenance

treatment, and fixed dose oral combinations for specific patient populations and expanded indications.”

Recent and Upcoming Milestones

Aleniglipron - Oral Small Molecule

Selective Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist for the Treatment of Obesity and Overweight

In March 2026, the Company reported data from the aleniglipron clinical program included

44-week topline data from the Phase 2 ACCESS II study, as well as interim data from body composition study and Phase 2b ACCESS open label

extension (OLE) study.

The

Phase 2 ACCESS II study demonstrated a placebo-adjusted mean weight loss of 16.3% (39 Ibs;

p<0.0001) at the 180 mg dose and 16.0% (37 Ibs; p<0.0001) at the 240 mg dose at 44

weeks.

The

ongoing ACCESS OLE study achieved continued weight loss up to 16.2% (40.5 lbs) observed with

120 mg dose at 56 weeks.

weight loss plateau was observed in any of the studies.

Data from the ACCESS, ACCESS II, Body

Composition, and the ACCESS OLE studies provide a strong foundation for the decision to advance aleniglipron into Phase 3 clinical development.

The Company expects to report topline results from the ACCESS OLE and Body Composition studies in Q3 and Q4 2026, respectively.

The Company received positive end-of-Phase

2 feedback from the U.S. Food and Drug Administration (FDA) and clear guidance on the Phase 3 program with

a starting titration dose of 2.5 mg and the intent to evaluate multiple doses. The Company anticipates initiating the Phase 3 program

in Q3 2026.

The Company is also conducting supplementary

studies to enhance the competitive profile of aleniglipron, including:

Ongoing study of ACCESS OLE to

evaluate the tolerability profile of the dosing regimen starting at the 2.5 mg dose for those previously on placebo and to collect

up to 72 weeks of data exposure to aleniglipron, including 180 mg dose. Data are expected in Q3 2026.

Ongoing

Body Composition study to assess the effect of aleniglipron on body fat loss over a 44-week

evaluation period, which includes a 28-week titration period and a starting dose of 2.5 mg

and target dose of 180 mg of aleniglipron. These data will be used to inform the size of

a sub study into the Phase 3 program. Data are expected in Q4 2026.

Ongoing

30-week study in patients with type 2 diabetes mellitus (T2DM) with obesity/overweight and a starting dose of 2.5 mg and target dose of 180 mg of aleniglipron to

evaluate the potential for including participants with T2DM in the Phase 3 obesity program.

Data are expected in Q4 2026.

Ongoing

SWITCH study to assess the transition or switching from an approved injectable GLP-1 receptor

agonist to once-daily oral aleniglipron for weight loss maintenance. This study assesses

different aleniglipron starting doses and weight loss maintenance over 12 weeks. Data are expected

in Q4 2026.

Oral Small Molecule Amylin Receptor

Agonists

December 2025, the Company advanced ACCG-2671 into a Phase 1 clinical study as the industry’s

most advanced oral small molecule amylin therapy for the treatment of obesity. ACCG-2671

is being evaluated in an ongoing single ascending dose (SAD) study to measure safety, tolerability,

pharmacokinetics, and food-effect of single ascending doses in healthy adult participants with data anticipated in 2H 2026. In addition, the Company expects to initiate a multiple ascending dose (MAD) study in Q3 2026.

November 2025, the Company declared a second oral small molecule dual amylin calcitonin

receptor agonist development candidate, ACCG-3535. ACCG-3535, which is a unique chemical

structure compared to ACCG-2671, demonstrated robust food intake suppression and significant,

dose-dependent body weight reduction as a monotherapy in diet-induced obese rats. Combination

therapy with semaglutide (both concurrently and as a subsequent add-on to semaglutide) resulted

in superior weight loss compared to semaglutide or ACCG-3535 monotherapy. The Company

expects to initiate a Phase 1 clinical study of ACCG-3535 in Q4 2026.

Multiple presentations at ADA, taking

place from June 5–8, 2026

Details of the presentations are as

follows:

Title: ACCESS Trial: Dose-Ranging

Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with

Obesity and Overweight

Session: Oral Presentations -

Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making (1032-OR)

Speaker: Julio Rosenstock, MD,

University of Texas Southwestern Medical Center

Date: Friday, June 5: 12:45

p.m. – 1:00 p.m. CT

Title: Safety, Tolerability,

and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial

Session: General Poster Session

(2637-P)

Date: Monday, June 8: 12:30

p.m. – 1:30 p.m. CT

Title: Exploring a Lower Starting

Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials

Session: Late Breaking Poster

Session (3101-LB)

Date: Sunday, June 7: 12:30

p.m. – 1:30 p.m. CT

Title: Combination Treatment

of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional

Weight Loss than Monotreatment in Obese NHPs

Session: Late Breaking Poster

Session (3061-LB)

Date: Sunday, June 7: 12:30

p.m. – 1:30 p.m. CT

Title: Comparison of Conditioned

Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists

Session: Late Breaking Poster

Session (3062-LB)

Date: Sunday, June 7: 12:30

p.m. – 1:30 p.m. CT

Additional information about the ADA

2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).

First Quarter 2026 Financial Highlights

Cash Position: Cash, cash equivalents

and short-term investments totaled $1.5 billion as of March 31, 2026. The Company received $100.0 million in the first quarter of

2026, consisting of an upfront license fee for certain patents that cover a class of oral GLP-1 receptor agonists that is different from

aleniglipron. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key

clinical milestones through the end of 2028. This includes costs related to the ongoing aleniglipron ACCESS OLE, ACCESS II extension

study, the supplementary studies, and Phase 3 registrational studies in chronic weight management, but excludes additional costs related

to pre-commercialization activities including commercial manufacturing.

Research and Development (R&D) Expenses: R&D

expenses for the first quarter of 2026 were $66.5 million, as compared to $42.9 million for the same period in 2025. The increase in

R&D expenses was primarily due to increases related to clinical trial costs, preclinical research and development expenses and employee

expenses (primarily due to an increase in personnel) to support the advancement of our GLP-1R franchise including aleniglipron.

General and Administrative (G&A)

Expenses: G&A expenses for the first quarter of 2026 were $22.9 million, as compared to $13.4 million for the same period in

2025. The increase in G&A expenses was primarily due to increases in employee expenses as we expanded our infrastructure to drive

and support the growth in our operations and professional services.

Net Loss: Net loss for the first

quarter of 2026 totaled $76.0 million, with non-cash share-based compensation expense of $11.6 million, compared to $46.8 million for

the same period in 2025 with non-cash share-based compensation expense of $5.9 million.

About Aleniglipron and Structure

Therapeutics’ Oral Metabolic Franchise

Aleniglipron (GSBR-1290) is an investigational

orally-available, small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of obesity and T2DM. Through

Structure Therapeutics’ structure-based drug discovery platform, aleniglipron was designed to be a biased G Protein-Coupled Receptor

(GPCR) agonist, which selectively activates the G-protein signaling pathway. Beyond aleniglipron, Structure Therapeutics is developing

next generation oral small molecules including amylin receptor agonists (ACCG-2671 and ACCG-3535), and other combination GLP-1 receptor

agonists candidates targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon and apelin receptors.

About Structure Therapeutics

Structure Therapeutics is a science-driven

clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic

metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the

Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule

compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people

living with obesity around the world. For additional information, please visit www.structuretx.com.

Forward-Looking Statements

This press release contains “forward-looking

statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without

limitation, statements concerning: the Company’s future plans and prospects; the expected timing of ACCESS OLE and Body Composition

studies data readouts; the planned initiation of the aleniglipron Phase 3 study and the timing thereof; the expected timing of initial

data from the Phase 1 study of ACCG-2671; the planned initiation of the ACCG-3535 Phase 1 study and the timing thereof; the belief that

data to date from the ACCESS, ACCESS II, Body Composition, and the ACCESS OLE studies support and inform aleniglipron advancement into

Phase 3 clinical development; the Company’s anticipated cash runway and uses of cash; any expectations regarding the potential

benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects

and future application of aleniglipron; any presumption that topline, interim or preliminary data will be representative of final data

or data in later clinical trials. In addition, when or if used in this press release, the words and phrases "anticipated,"

"believe," "expect," "potential," "to be," "will," and similar expressions and their

variants, as they relate to the Company, may identify forward-looking statements. Forward-looking statements are neither historical facts

nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are

reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results,

levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's

forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related

to topline results that the Company reports are based on preliminary analysis of key efficacy and safety data, and such data may change

following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the

complete results of a clinical trial; the preliminary nature of the results due to the length of the study and sample size and the results

from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and

completion of the Company's planned Phase 3 clinical program and other clinical studies; disruptions to the operations of the FDA or

other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, or staffing

reductions; the Company's ability to advance aleniglipron, ACCG-2671, LTSE-2578, ACCG-3535, and its other therapeutic candidates, obtain

regulatory approval of, and ultimately commercialize the Company's therapeutic candidates; competitive products or approaches limiting

the commercial value of the Company's product candidates; the timing and results of preclinical and clinical studies; the Company's ability

to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations,

manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeconomic conditions,

including as a result of tariffs and various global conflicts; the Company's ability to protect its intellectual property; and other

risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's

latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements

contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates

as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist

after the date on which they were made, except as required by law.

Investors:

Corey Davis, Ph.D.

LifeSci Advisors, LLC

212-915-2577

cdavis@lifesciadvisors.com

Jun Yoon

Structure Therapeutics Inc.

ir@structuretx.com

Media:

Dan Budwick

1AB

Dan@1abmedia.com

STRUCTURE THERAPEUTICS INC.

Condensed Consolidated Statements

of Operations

(unaudited)

(In thousands)

THREE MONTHS ENDED

MARCH 31,

2026

2025

Operating expenses:

Research and development

$ 66,507

$ 42,867

General and administrative

22,872

13,444

Total operating expenses

89,379

56,311

Loss from operations

(89,379 )

(56,311 )

Interest and other income, net

13,601

9,576

Loss before provision for income taxes

(75,778 )

(46,735 )

Provision for (benefit from) income taxes

190

Net loss

$ (75,968 )

$ (46,833 )

STRUCTURE THERAPEUTICS INC.

Condensed Consolidated Balance Sheet

Data

(unaudited)

(In thousands)

MARCH 31,

DECEMBER 31,

2026

2025

Assets

Current assets:

Cash, cash equivalents and short-term investments

$ 1,458,504

$ 1,446,197

Prepaid expenses and other current assets

32,094

124,106

Total current assets

1,490,598

1,570,303

Property and equipment, net

6,365

6,653

Operating right-of-use assets

5,606

6,245

Other non-current assets

5,555

717

Total assets

$ 1,508,124

$ 1,583,918

Liabilities and shareholders’ equity

Current liabilities:

Accounts payable

$ 7,822

$ 13,864

Accrued expenses and other current liabilities

46,553

46,543

Operating lease liabilities, current portion

2,609

2,878

Total current liabilities

56,984

63,285

Operating lease liabilities, net of current portion

3,183

3,609

Other non-current liabilities

863

647

Total liabilities

61,030

67,541

Total shareholders’ equity

1,447,094

1,516,377

Total liabilities and shareholders’ equity

$ 1,508,124

$ 1,583,918

GRAPHIC

Filename: tm2613721d1_8kimg01.jpg · Sequence: 9

Binary file (5150 bytes)

Download tm2613721d1_8kimg01.jpg

GRAPHIC

Filename: tm2613721d1_8kimg02.jpg · Sequence: 10

Binary file (4507 bytes)

Download tm2613721d1_8kimg02.jpg

GRAPHIC

Filename: tm2613721d1_ex99-1img01.jpg · Sequence: 11

Binary file (6051 bytes)

Download tm2613721d1_ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 13

v3.26.1

Cover

May 07, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-41608

Entity Registrant Name

Structure

Therapeutics Inc.

Entity Central Index Key

0001888886

Entity Tax Identification Number

98-1480821

Entity Incorporation, State or Country Code

Entity Address, Address Line One

601

Gateway Blvd.

Entity Address, Address Line Two

Suite

900

Entity Address, City or Town

South

San Francisco

Entity Address, State or Province

Entity Address, Postal Zip Code

94080

City Area Code

650

Local Phone Number

457-1978

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

American Depositary Shares Adss Each Representing Three Ordinary Shares Par Value 0. 0001 Per Ordinary Share [Member]

Title of 12(b) Security

American

Depositary Shares (ADSs), each representing three

ordinary shares, par value $0.0001 per ordinary share

Trading Symbol

GPCR

Security Exchange Name

NASDAQ

Ordinary Shares Par Value 0. 0001 Per Share [Member]

Title of 12(b) Security

Ordinary

shares, par value $0.0001 per share*

No Trading Symbol Flag

true

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true only for a security having no trading symbol.

+ References

No definition available.

+ Details

Name:

dei_NoTradingSymbolFlag

Namespace Prefix:

dei_

Data Type:

dei:trueItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=gpcr_OrdinarySharesParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: